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1 Summary 
Chromosomal instability (CIN) is one of the hallmarks of cancer and is found to be a 
characteristic property of most solid tumors. However, only little is known about the exact 
mechanisms leading to CIN. On the other hand, CIN is known to drive tumor cell evolution 
by clonal expansion leading to tumor heterogeneity, providing proliferative advantage, 
metastatic potential and chemoresistance to tumor cells. Hence, it is of utmost importance 
to identify causal mutations and delineate the mechanisms involved in CIN development in 
order to design targeted treatments for such notorious tumors.  
In this thesis, I analyzed the NCH149 cell line derived from a primary glioblastoma tumor 
that is highly resistant to chemo- and radiotherapy. Cytogenetic analysis of this cell line 
revealed extraordinary aneuploidy, clonal heterogeneity and CIN. We could further 
demonstrate that mitotic chromosome segregation defects and centriole amplification were 
the causes of CIN in NCH149 cells.  
With the aim to identify mutated genes that might contribute to the CIN phenotype of 
NCH149 cells whole exome sequencing was performed. This led to the identification of a 
novel mutation in the tumor suppressor gene LATS1. Functional characterization of LATS1 
protein showed that the identified mutation (p.I615V) interferes with YAP1 binding and 
prevents phosphorylation of YAP1 causing its nuclear localization. Overexpression of 
constructs harboring the identified LATS1 mutation influenced the subcellular localization of 
YAP1. In addition, micronucleus formation and centriole over-duplication was induced by 
overexpression of mutant LATS1. In addition, we could show that hyperactive YAP1 in 
NCH149 cells, which is due to mutated LATS1, is an effective drug target to induce 
cytotoxicity to highly resistant NCH149. Verteporfin, an inhibitor of the transcriptional 
activity of YAP1, prevents the transcription of downstream targets and by this specifically 
kills LATS1-mutant NCH149 cells compared to LATS1 wild type NCH82 glioblastoma cells.    
Therefore, this study demonstrates that LATS1 plays a key role in maintaining genomic 
integrity. Mutant LATS1 causes loss of YAP1 oncogene negative regulation and leads to the 
development of CIN. In addition, Verteporfin has been identified as a targeted cytotoxic 
agent against LATS1 mutant cells. 
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2 Zusammenfassung 
Chromosomale Instabilität (CIN) ist ein Charakteristikum von Krebs und in den meisten soliden 
Tumoren zu finden. CIN beschleunigt die Tumorentwicklung durch klonale Evolution, die zu 
Tumorheterogenität, beschleunigter Proliferation, Metastasierung und Resistenz gegenüber 
Chemotherapie führt. Allerdings ist über die genauen Mechanismen, die zur Enstehung von 
CIN führen, wenig bekannt. Daher ist es von großer Bedeutung, ursächliche Mutationen und 
die an der Entwicklung von CIN beteiligten Mechanismen zu identifizieren, um eine gezielte 
Behandlung von Tumoren mit CIN zu ermöglichen. 
In dieser Arbeit wurde die NCH149-Zelllinie, die aus einem primären Glioblastom generiert 
wurde und die eine ausgeprägte Resistenz gegenüber Chemo- und Strahlentherapie aufweist, 
untersucht. Zytogenetische Analysen zeigten, dass diese Zellen hochgradig aneuploid und 
sehr heterogen und somit chromosomal instabil sind. Weiter konnte gezeigt werden, dass CIN 
in diesen Zellen auf fehlerhafte Chromosomensegregation während der Mitose und eine 
Zentriolenamplifikation zurückzuführen ist. 
Zur Identifikation von Mutationen, die ursächlich für den hohen Grad an CIN in diesen Zellen 
sein können, wurde das gesamte Exom der NCH149-Zellen sequenziert. Dabei wurde eine 
neue Mutation im Tumorsuppressorgen LATS1 identifiziert. Funktionelle Analysen dieser 
Mutation (p.I615V) zeigten, dass die Mutation die Interaktion von LATS1 und YAP1 verhindert, 
wodurch YAP1 nicht phosphoryliert wird und dadurch im Zellkern lokalisiert. Überexpression 
eines LATS1-Konstrukts, das die Mutation enthält, führt ebenfalls zu einer vermehrt nukleären 
YAP1-Lokalisation. Zudem führt die Überexpression von mutiertem LATS1 zur Bildung von 
Micronuclei und zur Zentriolenamplifikation. Weiter konnte ich diese LATS1-Mutation und die 
daraus resultierende YAP1-Hyperaktivität als ein therapeutisches Target identifizieren, um 
NCH149-Zellen, die sonst resistent gegenüber Standardbehandlungen sind, gezielt zu töten. 
Die Behandlung von Zellen mit Verteporfin, dass die transkriptionelle Aktivität von YAP1 
inhibiert, zeigt, führte zum Absterben LATS1-mutierter NCH149-Zellen, wohingegen LATS1-
Wildtyp NCH82-Glioblastomzellen durch Verteporfin nicht beeinflusst wurden. 
Zusammenfassend zeigt sich, dass LATS1 für die Integrität des Genoms von Zellen von großer 
Bedeutung ist. Die identifizierte LATS1-Mutation hat einen Verlust der Regulation des YAP1-
Onkogens und somit die Entstehung von CIN zur Folge. Zudem konnte Verteporfin als ein 
spezifisch gegen LATS1-mutierte Zellen wirkendes Chemotherapeutikum identifiziert werden. 
                                                                                                                                Introduction 
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3 Introduction 
3.1 Chromosomal Instability 
Chromosomal Instability (CIN) is defined as a persistent high rate of gain or loss of 
chromosomes (1). These gains and losses of chromosomes are manifested as aneuploidy; 
an abnormal karyotype of a cell (2). Although, aneuploidy is the ultimate consequence of 
CIN and could be a measure of the degree of CIN, these terms can not be used 
interchangeably (3). CIN is a dynamic process of changes in the cellular chromosome 
content over generations resulting in aneuploidy. Aneuploidy on the other hand is a 
description of a cellular state, it specifically describes a cell whose karyotype is not a 
multiple of the haploid complement (4). In contrast to CIN, aneuploidy may develop from a 
transient chromosomal aberration event during the development of the cell leading to the 
abnormal karyotype that is subsequently stably propagated and inherited. For instance, 
Down syndrome is caused only due to trisomy (gain of a single copy) of chromosome 21 
while the rest of the chromosome content is unperturbed. Therefore it can be stated that all 
chromosomally instable cells are aneuploid but aneuploid cells are not necessarily 
chromosomally instable (5). 
CIN can be broadly divided into two categories: structural and numerical CIN. Structural CIN 
encompasses subtle sequence instabilities represented by amplifications, inversions, 
translocations, deletions, and other events such as NER-associated instability (NIN) or 
microsatellite instability (MIN) (6). Numerical instability on the other hand includes gains and 
losses of whole chromosomes. This work is focused on the causes of numerical CIN and 
the resulting aneuploidy and its role in disease development and progression. 
CIN is most often a result of defects in the machinery responsible for faithful chromosome 
segregation during mitosis. These defects could arise either through mutation of genes 
encoding mitotic proteins or by imbalances in protein levels or activities that reduce mitotic 
fidelity (7). To gain a better understanding of the development of CIN it is important to look 
into the process of cell division in greater detail. 
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3.2 The Cell Cycle 
The cell cycle is described as the period and the sum of all biochemical processes between 
the emergence of a cell from a mother cell and its division into two daughter cells (8). The 
eukaryotic cell cycle is divided in four successive phases (M, G1, S, G2). The M-phase 
(division phase) includes mitosis (nuclear division) and cytokinesis (division of 
cytoplasm/cell). The interval between two M-phases is termed interphase which includes 
G1-, S- and G2-phases of the cell cycle. The term G1 (gap 1) describes the period between 
M-phase and S-phase. In the S-phase (synthesis phase) replication of nuclear DNA takes 
place. The G2-phase falls between S phase and M phase wherein the connections with 
neighboring cells are dissolved to prepare for mitosis.  
Mitosis involves a sequence of events that culminate in the production of new (daughter) 
cells that are genetically identical to the original (mother) cell (9). This requires precise 
orchestration of three major events: entry into mitosis, chromosomal segregation, and 
cytokinesis which are distributed over four stages: prophase, metaphase, anaphase and 
telophase. In prophase chromosomes are condensed and the spindle apparatus starts to 
build up. With the beginning of metaphase (prometaphase) the nuclear envelope breaks 
down and the spindle microtubules are formed that attach to the kinetochores (protein 
structure on chromatids) of the chromosomes. During metaphase chromosomes are 
arranged at the equatorial plane of the cell and the spindle apparatus is fully formed. 
Anaphase marks the separation of sister chromatids leading to their segregation to the two 
spindle poles. In parallel, the microtubules lengthen moving the spindle poles apart. In 
telophase a new nuclear membrane is formed around the two sets of chromosomes at each 
pole and the contractile ring is formed. During cytokinesis the contractile ring ingresses 
forming the cleavage furrow eventually separating the daughter cells.   
The cell cycle phases are subject to strict control by various control mechanisms referred to 
as "checkpoints", which verify whether the requirements for the cell to pass to the next 
phase of the cell cycle have been fulfilled (Figure 3.1) (10). 
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Figure 3.1 The cell cycle and its checkpoints 
The cell cycle is divided into four phases: S-phase (synthesis phase), M-phase (mitosis phase), and 
the G1- and G2-phases (Gap-phases). Checkpoints regulating the various phases of cell cycle are 
indicated. Albert, B. et al. (2008) Molecular biology of the cell. New York, USA: Garland Science. 
 
3.3 Cell cycle checkpoints 
The first checkpoint within the course of the cell cycle is called the restriction point or G1-
checkpoint, which occurs at the end of G1-phase of the cell cycle. At the G1-checkpoint 
decided whether or not the cell is allowed to divide depending on the environmental 
condition. Under unfavorable conditions cells can either delay entry intro S-phase or enter 
the resting G0-stage (11).  
The cell encounters a second checkpoint at the G2-M boundary called the DNA damage 
checkpoint or S-phase checkpoint. This ensures that the cells do not enter mitosis with 
damaged DNA that may have accumulated during S-phase. DNA repair proteins (e.g. ATM, 
ATR) that localize to sites of DNA damage in G2-phase initiate a signaling cascade that 
regulates mitotic entry via Cdk1-cyclin B (12).  
Third, the spindle assembly checkpoint (SAC) or mitotic checkpoint ensures that 
chromosome segregation proceeds error free thereby preventing aneuploidy. During 
mitosis, this checkpoint inhibits anaphase onset until all chromosomes are properly 
attached to the spindle and the kinetochores of the sister chromatids are correctly attached 
to opposite spindle poles, ensuring their proper segregation (13). A mitotic checkpoint 
                                                                                                                                Introduction 
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complex (MCC) comprising of MAD2, BUBR1/Mad3 and BUB3, assembles at unoccupied 
kinetochores (14). This complex negatively regulates the ability of CDC20 to activate 
APC/C-mediated polyubiquitinylation of cyclin B and securin, thereby preventing separation 
of sister chromatids and exit from mitosis, respectively. Securin is a stoichiometric inhibitor 
of separase which is required to cleave the cohesin complex that holds sister chromatids 
together, and cohesin cleavage is required to execute anaphase. On the other hand, 
proteolysis of cyclin B by APC/C inactivates CDK1, which promotes mitotic exit (15). Hence, 
by keeping CDC20 in check, the SAC prolongs metaphase until all chromosomes have 
become bi-orientated between separated spindle poles on the metaphase plate. Even a 
single unattached kinetochore is sufficient to delay anaphase onset indicating the efficiency 
of this checkpoint. 
3.4 Causes of CIN 
Deregulation of proteins involved in chromosome condensation, sister-chromatid cohesion, 
kinetochore structure and function, centrosome/microtubule formation and dynamics and 
checkpoint genes that monitor the proper progression of the cell cycle can lead to CIN (16). 
The pathways by which cells can gain or lose chromosomes during mitosis are described 
below (Figure 3.2). 
3.4.1 Defects in cell cycle checkpoints 
The first defect that was proposed to play a causal role in CIN was a defect in the spindle 
assembly checkpoint (SAC) (17). Impairment of the mitotic checkpoint due to reduction in 
levels of one or more checkpoint components might allow cells to enter anaphase in the 
presence of unattached or misaligned chromosomes. As a consequence, both copies of 
one or more replicated chromosomes are deposited in the same daughter cell (non-
disjunction errors) causing aneuploidy (18). 
Mitotic checkpoint errors can give rise to aneuploidy or lead to cell death, depending on the 
extent of checkpoint malfunction. Complete inactivation of the mitotic checkpoint resulting 
from elimination of key components such as MAD2 or BUBR1 leads to extensive aneuploidy 
and massive chromosome missegregation, which is lethal for cells (19). Studies in mice 
have shown that weakened SAC activity is associated with a high incidence of aneuploidy 
and tumorigenesis (20; 21). However, meanwhile it has been shown that most aneuploid 
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human cancer cells have a functional SAC indicating that loss of SAC function seems not to 
play a major role in CIN induction in human tumors. However, despite extensive search, 
large-scale genome sequencing has revealed very few mutations in genes that encode 
proteins involved in SAC have been found in human tumors (22; 23).  
 
 
Figure 3.2 Pathways to chromosomal missegregation 
Mechanisms of chromosomal missegregation include mitotic checkpoint defects (A), cohesion 
defects (B), merotelic microtubule-kinetochore attachments (C) and supernumerary centrosomes 
which, by themselves, lead to merotelic microtubule-kinetochore attachments again (D). Modified 
from Holland et al., Nature, 2009, with permission. 
 
 
A) Mitotic checkpoint defects B) Cohesion defects C) Merotelic attachments
D) Supernumerary centrosomes
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3.4.2 Chromosomal missegregation  
Mitotic errors leading to aneuploidy can occur despite intact mitotic checkpoint signaling. 
During mitosis, faithful segregation of chromosomes relies on the bi-oriented attachment of 
kinetochores to spindle microtubules (k-MT attachments) called amphitelic attachments, 
meaning that each kinetochore binds to microtubules oriented toward only one spindle pole, 
thereby generating centromeric tension that satisfies the SAC (24). Kinetochores in human 
cells bind approximately 20 microtubules and errors in k-MT attachments lead to 
missegregation of chromosomes. In chromosomally instable cells missegregation of 
chromosomes is found on an average, once in every one to five cell divisions (25). 
Erroneous k-MT attachments frequently occur during prophase when (i) one of the sister 
kinetochores is left unattached (monotelic attachment), (ii) when both sister kinetochores 
become attached to microtubules from the same pole (syntelic attachment) or when (i) a 
single kinetochore attaches to microtubules arising from both spindle poles rather than just 
one (merotelic attachment) (Figure 3.3). Monotelic and syntelic configurations fail to satisfy 
the SAC because not all kinetochores are bound to microtubules or no centromeric tension 
is generated and are therefore detected by the spindle checkpoint. In contrast, merotely 
avoids detection by the SAC since kinetochores attain full occupancy by microtubules 
despite improper orientation and centromeric tension is generated as well (26). Therefore, 
undetected by the SAC, merotelic attachments can cause sister chromatids to either be 
pulled towards the same pole into one daughter nucleus (chromosome non-disjunction) or 
left behind in the spindle midzone (lagging chromosomes), thereby often excluding them 
from both the daughter nuclei resulting in micronucleus formation (27). Studies have shown 
that on average about 21% of daughter cell pairs of CIN cells have micronuclei (28). 
Destabilization of erroneous k-MT attachments is essential for their correction and was 
found to restore faithful chromosome segregation to CIN cells, indicating a causal 
relationship between k-MT attachment errors and CIN (29). Correspondingly, it has been 
shown that chromosomally instable cells often have hyperstable k-MT attachments, which 
impairs their ability for faulty attachment correction (30). 
Another defect that contributes to chromosomal missegregation is premature loss of sister 
chromatid cohesion. Maintenance of cohesion between the two sister centromeres until 
anaphase onset is essential for proper chromosome segregation. Duplicated sister 
chromatids are held together until anaphase by the cohesin complex ensuring proper k-MT 
attachments and centromeric tension needed for proper segregation. Premature loss of 
sister chromatid cohesion causes the sister chromatids to separate and float in the cellular 
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space. Overexpression of separase, cohesin complex subunits or dysfunctional securin has 
been shown to cause a loss of proper sister chromatid cohesion (31). As a consequence, 
sister chromatids fail to segregate equally between the daughter cells leading to aneuploidy. 
Emerging cancer genomics studies have documented that cohesin genes are a frequent 
target of somatic alterations in a number of tumor types including glioblastoma, Ewing 
sarcoma, urothelial carcinoma and acute myeloid leukemia (32).  
 
3.4.3 Supernumerary centrosomes 
Centrosomes are important regulators of cell-cycle progression, serving as the main 
microtubule-organizing centers (MTOC) to form k-MT attachments and aid faithful 
segregation of chromosomes during mitosis. A centrosome is composed of a pair of 
centrioles and a surrounding amorphous cloud of pericentriolar material (PCM). Centrosome 
number is tightly regulated during the cell cycle such that a centrosome duplicates in S 
phase and separates at mitotic entry. However, defects in the centrosome duplication 
machinery lead to supernumerary centrosomes (33; 34; 35). Presence of supernumerary 
(extra) centrosomes leads to the formation of multiple spindle poles during mitosis followed 
by multipolar division. Multipolar divisions give rise to highly aneuploid daughter cells, which 
 
Figure 3.2 Types of k-MT attcahments 
The various types of kinetochore-microtubule attachments include: A) correct amphitelic microtubule 
attchment to the sister kinetochores that attains the right centromeric tension (green) and therefore 
does not activate SAC (green). B) and C) erroneous attachments where only one (monotelic) or both 
sister kinetochores (syntelic) are attached to microtubules from the same spindle pole do not lead to 
correct centromeric tension (red), causing SAC activation (green) and subsequent correction to 
proper k-MT attachment. D) Merotelic attachment, where one of the kinetochores is attached 
aberrantly to microtubules form both spindle poles and since the kinetochores attain full occupancy 
of microtubules centromeric tension is falsely satisfied (red) which avoids detection by the SAC (red) 
causing chromosomal missegregation. 
A) Amphitelic B) Monotelic C) Syntelic D) Merotelic
Centromeric 
tension
SAC 
activation
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are usually unviable (36). In order to generate viable daughter cells, supernumerary 
centrosomes are often found to be clustered together to form two groups, allowing cells to 
divide in a pseudo-bipolar fashion (37; 38). This mechanism is termed centrosomal 
clustering. The frequency of multipolar spindles is found to be higher in prometaphase than 
in anaphase confirming that centrosomes cluster to promote bipolar spindle formation prior 
to anaphase onset (39). 
Interestingly, extra centrosomes are capable of driving chromosome missegregation 
through a mechanism independent of multipolar divisions. Studies have shown that the 
process of centrosomal clustering via transient multipolar spindle formation increases the 
propensity of merotelic k-MT attachments leading to chromosome missegregation (40).  
Thus, the presence of extra centrosomes accompanied by centrosomal clustering increases 
the rate of k-MT attachment errors leading to CIN. Notably, the presence of extra 
centrosomes and clustering mechanisms prolong the duration of mitosis by delaying 
satisfaction of the SAC (41; 42). Although a majority of the cells with extra centrosomes 
divide bipolarly with missegregated chromosomes, some cells die during the prolonged 
mitotic arrest and some others remain without undergoing cytokinesis and end up as a 
single tetraploid G1 cell (43).  
3.5 Consequences of CIN 
Mutation-induced mitotic checkpoint relaxation, defects in chromatid cohesion, merotelic 
attachments of microtubules to kinetochores, and supernumerary centrosomes cause 
chromosome missegregation resulting in aneuploid cells. Aneuploidy is marked by altered 
chromosome copy number leading to changes in the level of transcripts of affected genes. 
This in turn translates into protein dosage changes that can alter the balanced stoichiometry 
of various complexes or pathways leading to malfunctioning of corresponding biological 
processes. When proteins involved in various mitotic processes are affected, it may lead to 
errors causing further CIN and thus contributing to aneuploidy generation (44). Hence, 
chromosomally instable cells enter a vicious circle of events leading to continuous genomic 
instability which might be beneficial or disadvantageous to a cell. 
In theory, the direct consequences of CIN should be disadvantageous for cell proliferation 
and survival. The lack of essential genes produced by random aneuploidy may adversely 
effect survival and the aberrant genome would risk detection by selection barriers (e.g. 
checkpoints) resulting in elimination. If the accumulated damage rises above the threshold  
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for viability, apoptotic pathways are activated and cell death ensues. However, CIN gives 
rise to heterogeneity, which might prove beneficial for survival. The heterogeneity in the 
population of a given cell mass arising as a result of CIN ensures that at least some of the 
cells contain the required genetic alteration to overcome selection barriers and continue 
proliferation (45). Heterogeneity allows cells to survive and adapt to changing 
microenvironments giving cells proliferative advantages (46). 
Such adaptive interactions can provide opportunities for chromosomally instable cells to 
survive and evolve to suit the microenvironment, in a manner comparable to Darwinian 
theory of natural selection. Hence, by clonal evolution, an aberrant karyotype is established, 
which has optimal chances of survival, proliferation and resistance to internal and external 
elimination pressure, which are the characteristic features of most cancer cells. Indeed, 
various studies show that CIN plays a crucial role in the development of cancer (47; 48).  
3.6 Role of CIN in Cancer 
The presence of aneuploid chromosome contents in tumor cells has been common 
knowledge for over 100 years. The foundations for viewing cancer as a genetic disease 
were laid as early as 1890 when David von Hansemann postulated that aberrant cell 
divisions are responsible for the decreased or increased chromatin content found in cancer 
cells. Theodor Boveri found the association between aberrant mitoses, aneuploidy and 
malignancy – Boveri, T. Zur Frage der Entstehung Maligner Tumoren; Gustav Fisher, Jena, 
1914. Today, it has been demonstrated that 68% of all solid tumors have numerical 
variations in their chromosomes number, i.e. they are aneuploid (49). In a study by Lengauer 
et al., fluorescence in situ hybridization (FISH) was used to show that losses or gains of 
multiple chromosomes occurred as often as 10-100 times more often in aneuploid 
colorectal cancer cell lines than in normal cells. Karyoptypic analyses show that tumors 
display both intra- and intertumor heterogeneity suggesting that most tumors are not only 
aneuploid, but also chromosomally instable. As CIN is found to be a characteristic property 
of most solid tumors, it has been regarded as a hallmark of cancer. Although scientific 
advances in recent years have permitted more refined analysis of the types of chromosomal 
abnormalities in cancer, the function of numerical chromosome aberrations in the etiology of 
cancer is less understood. A crucial question still remains unanswered: is CIN is a cause or 
a consequence of tumorigenesis? 
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The presence of CIN in cancer cells has been interpreted in two ways. One point of view 
portrays CIN and aneuploidy as a consequence of general chaos that accompanies 
malignant cells (50). The second point of view ascribes a causal importance to aneuploidy, 
arguing that it fuels tumorigenic progression (51). It has been established that cells have to 
acquire several genetic changes to allow tumorigenesis. It has been argued that the normal 
rate of mutation would be insufficient to provide the amount of genetic variation that is 
required for tumor growth, and hence it is often proposed that mutations causing genomic 
instability occur as the initiating event and act as a driving force of tumorigenesis (52).  
Tumors initiate as a result of one or more mutations that give a cell the selective growth 
advantage by means of CIN to overcome waves of clonal selection. As mentioned before 
CIN further drives adaptation by allowing tumors to constantly sample their 
microenvironment and attain the genetic changes necessary to propel tumor survival, 
proliferation and resistance to therapy. This model of mutation-driven genomic instability 
and tumorigenesis has been confirmed by numerous studies (53; 54).  
3.7 Genetic basis for CIN in cancers 
The concept that tumors develop through the accumulation of mutations in oncogenes and 
tumor suppressor genes is now a widely accepted fundamental principle of cancer biology. 
Although CIN aids faster accumulation of carcinogenic mutations, it still remains unclear 
what causes CIN itself. Mutations in genes with putative functions in guarding against 
chromosome missegregation and aberrant mitoses have been shown to cause CIN in rare 
cases (55).  
In theory, hundreds of human genes can be categorized as CIN causing genes, but only a 
few have been identified so far (56). These genes include hBUB1 and MAD2, proteins 
required for the proper functioning of the spindle assembly checkpoint (57; 58). Inherent 
mutations in BRCA1 and BRCA2 (involved in DNA repair and recombination, checkpoint 
control of the cell cycle and transcription) lead to high-grade familial breast cancer and CIN 
(59). Cyclin-dependent kinases (CDKs), the governors of cell cycle, are often found mutated 
or dysregulated in cancer cells, which manifests in an increased rate of cell cycling, cellular 
hyperproliferation and acquired genomic and chromosomal instability (60). In addition, 
studies have shown that overexpression of one of the two key regulators controlling sister 
chromatid cohesion, separase or securin, promotes CIN and oncogenic transformation (61). 
Moreover, mutational inactivation of genes encoding cohesin subunits such as STAG2 and 
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RAD21 have also been found in various human cancers (62).  
Michor and colleagues classify CIN genes based on the mutational events required to 
trigger instability (63). Class I CIN genes cause CIN if one allele of the gene is mutated or 
lost (e.g. MAD2) and class II CIN genes trigger CIN if one allele is mutated in a dominant- 
negative fashion (e.g. hBUB1). Thus, class I and II genes are called ‘single hit’ CIN genes. 
Class III CIN genes cause CIN only if both alleles are mutated (e.g. BRCA1 and BRCA2). 
Hence, a direct connection can be drawn between mutations in cell cycle components, 
tumor suppressor genes, oncogenes and CIN development. This provides evidence that 
CIN has a mutational origin and clues to the mechanistic basis of instability in cancers. 
3.8 Hippo pathway and cancer 
The mammalian Hippo pathway is a kinase cascade that plays a pivotal role in organ size 
control and tumor suppression by restricting proliferation and promoting apoptosis (64). The 
Hippo pathway was first identified in Drosophila by genetic mosaic screens for tumor 
suppressor genes. It is a highly conserved pathway, which in mammals includes two sets of 
core kinases MST1/2 and LATS1/2, which along with their respective co-activators SAV1 
and Mob1 form the backbone of the kinase cascade. The N-terminus of LATS1 contains 
two PPxY motifs (P, proline; X, any amino acid; Y, tyrosine), which bind to WW-domains 
(conserved tryptophans spaced 20-22 amino acids apart) of the transcriptional co-activators 
TAZ and YAP. When the pathway is active, Lats1/2 phosphorylates YAP and/or TAZ, which 
leads to cytoplasmic sequestration and degradation of these proteins. As consequence, 
TEAD 1-4 remains bound to VGL4 rendering it incapable of switching on the transcription of 
target genes. When the pathway is inactive, YAP/TAZ remain unphosphorylated and free to 
enter the nucleus and bind to TEAD1–4 resulting in context-dependent transcriptional 
output that mediates major physiological functions (Figure 1.3) (65). However, the regulatory 
mechanisms for the Hippo signaling pathway are not well understood (66). Numerous 
upstream regulators of the Hippo pathway have been identified recently, e.g. NF2/merlin-
mediated regulation involved in cell polarity as well as G-protein-coupled receptor (GPCR)-
dependent signaling for growth and proliferation. Lysophospholipid (LPA), sphingosine-1-
phosphate (S1P) or protease-activated receptors (PARs) bind to their corresponding 
membrane GPCRs and act through Rho-GTPases to activate YAP/TAZ (67). In addition, the 
actin cytoskeleton or mechanical tension appears to transmit upstream signals to the core 
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Hippo signaling cascade. Therefore, LATS-dependent modulation of YAP/TAZ activity 
appears to act as a focal point for different upstream cellular signals to Hippo pathway.  
 
 
Figure 3.3 The Hippo pathway 
Schematics of the core pathway components of the Hippo pathway and how they interact are 
depicted. A) When the pathway is on, proteins are phosphorylated resulting in cytoplasmic retention 
or degradation of YAP/TAZ. As a consequence TEAD1-4 remains bound to VGL4 rendering it 
incapable of switching on the transcription of target genes. B) When the pathway is off, un-
phosphorylated YAP/TAZ translocates to the nucleus and competitively binds to co-activators 
TEAD1-4 to switch the transcription of target genes on. Johnson et al. 2014, with permission. 
 
3.8.1 LATS1 and YAP1 
LATS1 is a member of the LATS/Warts tumor suppressor family. It is a putative 
serine/threonine kinase that belongs to AGC group (named after protein kinase A, G and C) 
and acts as a negative regulator of YAP1 in the Hippo signaling pathway. YAP1 is known to 
be an oncogene and shown to cause CIN and radioresistance in medulloblastoma (68). 
LATS1 localizes in the cytoplasm and to centrosomes during interphase and during mitosis. 
It is known to migrate to the mitotic spindle, spindle poles as well as the midbody during 
mitosis indicating its role in proper mitotic progression (69). During interphase, 
                                                                                                                                Introduction 
 18 
phosphorylated LATS1 phosphorylates YAP1 at Ser127, which leads to 14–3–3 binding and 
cytoplasmic sequestration followed by ubiquitination-dependent degradation of YAP1. In 
early mitosis LATS1 is dephosphorylated causing dephosphorylation of YAP1 and hence its 
nuclear localization leading to transcription of genes important for cell proliferation, cell 
death, and cell migration. Therefore, deregulation of LATS1-mediated sequestration of 
YAP1 in interphase causes YAP1 to translocate to the nucleus and prematurely activate 
transcription of cell growth proliferation and survival genes which is known to be associated 
with many cancer types (70). LATS1-mediated YAP1 phosphorylation is regulated by cell 
density in vitro in cultured cells and plays an important role in mediating cell contact 
inhibition. Upon reaching confluence (high density), YAP1 is found phosphorylated and 
localized to the cytoplasm of the cells whereas, at low density, YAP1 is predominantly 
localized in the nucleus (71). YAP1 expression levels and nuclear localization are found 
strongly elevated in some human cancers suggesting the loss of cell contact inhibition 
indicative of uncontrolled cell proliferation. 
In addition, LATS1 also functions in non-canonical Hippo signalling and Hippo-independent 
pathways. It has been shown that autophosphorylation of LATS1 during the G2/M transition 
plays a critical role in maintenance of ploidy through its actions in mitotic progression and 
G1 tetraploidy checkpoint. LATS1 regulates the cell cycle by modulating CDK1/Cyclin A 
activity (72). LATS1 with its protein-binding domain (PBD) is also known to bind and regulate 
the activity of MOB1, a regulatory protein of LATS1 and component of mitotic exit network 
(73). LATS1 interacts with regulators of actin filament assembly, Zyxin and LIMK1 indicating 
that LATS1 functions in mitosis and mechano-sensing independent of YAP/TAZ as well (74) 
(75). During the G2/M transition, YAP1 is found to be hyper-phosphorylated due to 
additional positive regulation of YAP1 by CDK1-mediated phoshorylation at T119 and S289. 
Defects in CDK1-mediated YAP1 phosphorylation were found to play a role in neoplastic 
transformation as they lead to mitotic defects and increased cell motility (76). This extensive 
involvement of LATS1 in important cellular functions elucidates its role in tumor suppression 
and maintenance of genomic integrity. 
Interestingly, studies of The Cancer Genome Atlas (TCGA) consortium show that LATS1 is 
infrequently mutated in human cancers (http://www.cbioportal.org/public-portal/) (Figure 
3.4). However, in a variety of human cancers upstream components of the pathway are 
downregulated through deletion or epigenetic mechanisms (e.g. deletion of NF2), with 
silencing of upstream components of the pathway leading to increased activity of the 
downstream effectors of YAP and TAZ. Experimental N-terminal truncation of LATS1 in 
mouse embryonic fibroblasts (MEFs) was found to cause abnormal cell growth and CIN in 
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nude mice (77). Decreased expression of LATS1 is correlated with progression and 
prognosis of glioma (78). This suggests that Hippo signaling is closely linked to tumor 
initiation and progression. 
  
 
 
 
 
Figure 3.3 LATS1 mutations in cancers 
Cross cancer histogram of LATS1 mutations obtained from cBioportal indicating a low frequency of 
mutations, deletions or amplifications of the LATS1 gene in patients with various cancer types. The 
graph includes data pooled together from 69 cancer genomics studies, from a total of 17584 cancer 
patient samples. Gao et al. 2013 & Cerami et al. 2012. 
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3.9 YAP1 inhibitors 
The complex relationship between CIN and cancer and the possible causal role of the Hippo 
pathway in CIN induction offer previously unrecognized means to limit tumor growth by 
pharmacological intervention. Although kinases are effective targets for small molecules, 
designing inhibitors to restore loss-of-function of kinases has been found to be a 
challenging task. Functionally, the most attractive targets for pharmacologic intervention 
with the Hippo pathway are the key proteins YAP and TAZ, which are the final common 
conduits of the entire pathway. Also, YAP is dispensable for the growth and homeostasis of 
normal tissues, thus potentially limiting the likelihood of side effects on healthy tissues (79). 
Since YAP and TAZ are the final downstream effectors, drug resistance achieved by 
alternative pathways can be, in theory, ruled out. Recent progress in the search for small-
molecule Hippo pathway modulators has identified Verteporfin (VP) and Dobutamine (a 
GPCR-beta adrenergic receptor antagonist) to be specific inhibitors of YAP1. Also, 
monoclonal antobodies (mAb’s) against LAP and SIP (YAP1 activators) has proven to be 
effective against YAP1 activity. Verteporfin is a benzoporphyrine derivative, a 
photosensitizer used for photodynamic therapy of macular degradation of the eye. VP 
disrupts YAP-TEAD transcriptional activation complex formation, hence, inhibiting YAP1 
activity (80). The porphyrin ring of VP disrupts the formation of the YAP–TEAD complex by 
binding to YAP and changing its conformation, thereby blocking the transcription of 
downstream targets. VP has already been be used as a chemotherapeutic agent for cancer 
cells overexpressing YAP1 in vitro (81). 
 
Figure 3.5 Structure of Verteporfin 
Verteporfin, a benzoporphyrin derivative, with its porphyrin ring disrupts the YAP-TEAD complex 
inhibiting its transcriptional activity. 
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3.10 Glioblastoma and CIN 
Gliomas are the most common primary malignant brain tumors in adults. The World Health 
Organization (WHO) classification distinguishes gliomas into four different grades of which 
Glioblastoma multiforme (GBM) is the fastest growing malignant type of brain tumor and 
accounts for about 15 percent of all brain tumors (82). Patients with GBM have a 
poor prognosis with a median survival of 15 months (83). GBM is know to be highly 
anaplastic and a morphologically highly heterogeneous tumor (84). Several studies showed 
that GBM samples harboring mutations of p53, or amplification of MDM2, epidermal growth 
factor receptor (EGFR) or mismatch repair (MMR) genes were typically chromosomally 
instable (85) (86) (87). GBM is also known to be remarkably resistant to chemotherapy and 
ionizing radiation. Resistance to treatment might be a consequence of CIN/aneuploidy, 
genetic alterations and intratumor heterogeneity, which are characteristics of these tumors. 
Understanding the genetic alterations, specific molecular biomarkers and proliferative 
pathways may promote development of effective therapeutic strategies for the management 
of GBM patients. Nevertheless, only little is known about patterns or exact mechanisms of 
CIN in GBM. 
3.11 GBM cell lines 
NCH149 and NCH82 are two cell lines derived form primary GBM tumors in the lab of Dr. C. 
Herold-Mende at the Department of Neurosurgery, University Hospital Heidelberg, Germany 
(88). Cytogenetic analysis of these cell lines revealed extraordinary aneuploidy in NCH149 
cells with chromosome numbers ranging from 42 to 129 and a few structural chromosome 
aberrations were observed namely t(13;17), isochromosome 7q, deletions 11q, 16p, and 
18p as well as unbalanced translocations der(13)t(11;13) and der(17)t(17;19), each of which 
were found in only 2 of 21 metaphase spreads analysed. NCH82 cells were found to have a 
near tetraploid karyotype and some recurrent unbalanced translocations like der(7)t(7;22) 
(observed in 14/15 metaphase spreads) and a deletion in the long arm of chromosome 22 
(in 15/15 metaphase spreads) were observed (89). This data indicates that NCH149 cells are 
possibly chromosomally instable while NCH82 cells are stablly tetraploid. 
  
                                                                                                                                Introduction 
 22 
3.12 Aim of this study 
Extensive literature evidence has suggested a direct link between CIN and the pathogenesis of 
various human malignancies. Nevertheless, the underlying molecular mechanisms of CIN 
development and resulting tumorigenesis remain undefined. Among a collection of primary 
GBM cultures one sample, the NCH149 cell line showed extensive numerical CIN and 
resistance against irradiation and cytotoxic agents was identified. With the aim to study the 
mechanism of massive numerical CIN, a comparative analysis of chromosomally instable 
(NCH149) and chromosomally stable (NCH82) patient-derived glioblastoma cell lines was 
performed. Using FISH as well as fluorescence microscopy the extent of CIN and the 
underlying mechanisms were investigated. 
Since it is discussed that mutation-induced aberrations in cellular mechanisms could lead to 
CIN, the mutation profile of the NCH149 GBM tumor cell line was assessed by whole exome 
sequencing. This profile was compared to the profile of cells of the associated primary tumor 
from which the cell line was derived as well as with healthy tissue from the patient. Dependent 
on the mutations detected in primary tumor and tumor cell line derived thereof, the role of the 
mutated genes for the development of CIN were investigated by microscopic, cell biological 
and biochemical techniques. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Biological materials  
4.1.1.1 Eukaryotic cell lines 
 
Table 4.: Eukaryotic cell lines  
Cell Lines Description Source / Reference 
Normal Human 
Astrocytes 
Cell line derived from 
primary astrocytes of a 
healthy donor. 
Catalog number: 1800 
Sciencell, CA, USA 
NCH149 Human Glioblastoma A. Régnier-Vigouroux, DKFZ, 
Heidelberg, Germany 
NCH82 Human Glioblastoma A. Régnier-Vigouroux, DKFZ, 
Heidelberg, Germany 
U2OS Human Osteosarcoma cell 
line 
Ponten and Saksela, 1967, 
ATCC HTB-96  
U2OS-Tet on Human Osteosarcoma cell 
line expressing tetracyclin 
(Tet)-regulated 
transactivator Tet-On 
Life technologies; Invitrogen, 
Carlsbad, USA 
 
4.1.1.2 Patient material 
Paraffin sections and DNA extracts of the parental tumor which was used to establish the 
NCH149 cell line as well as control brain tissue of the same patient were provided by C. 
Herold-Mende, University Hospital, Heidelberg (Tissue Bank of the National Center for 
Tumor Diseases (NCT) in Heidelberg, Germany). This material was used for fluorescence in 
situ hybridization (FISH) and whole exome sequencing experiments. 
 
                                                                                                               Materials and Methods 
 24 
4.1.1.3 Bacterial Material 
Table 4.1 Bacterial Material 
Name Genotype Source / Reference 
E. coli DH5 alpha  F- φ80lacZΔM15 Δ(lacZYA argF) 
U169recA1endA1 hsdR17 
(rKmK+) phoA supE44 thi-
1gyrA96 relA1 λ-  
Stratagene, USA  
 
 
4.1.1.4 Genetic material 
4.1.1.4.1 DNA primers    
All primers were ordered from Eurofins MWG Operon, Ebersberg, Germany. 
Table 4.2: List of Primers used for GATC sequencing, mutagenesis and PCR 
Nr. Name Use Sequence (5’-3’) 
1 LATS1_Mlu1 PCR AGTCAGCTGACGCGTATGGACTACAAAGA
CGATGACGACAAG 
2 LATS1_Sal1 PCR AGAGATATCGTCGACTTAAACATATACTAGA
TCGCGATTTTTAATCTCTGAG 
3 LATS1_Mut_s Mutagenesis AAGAAACAGATTACAACTTCACCTGTTACT
GTTAGGAAAAACAAGAAAG 
4 LATS1_Mut_as Mutagenesis CTTTCTTGTTTTTCCTAACAGTAACAGGTGA
AGTTGTAATCTGTTTCTT 
5 LATS1_PCR PCR ACCGCTTCAAATGTGACTGTGATGCCACCT 
6 LATS1_r_PCR PCR TCTACTTTTCTTGCTAGACAGACTTCACCA 
7 L3 Sanger 
Sequencing 
TGGGCATGAAATCCCTACA 
 
4.1.1.4.2 Expression plasmids 
Table 4.4: Expression Plasmids 
Vector Tag (terminus) Antibiotic Resistance  Source 
CMV-LATS1 2XFlag (N) Ampicillin Addgene 
pTRE2hyg - Ampicillin Clontech 
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4.1.1.4.3 Expression constructs 
Table 4.5: List of expression constructs 
Nr. Name Description Primer Source 
1 LATS1-wt-
pTRE2hyg 
Wild type LATS1 cDNA in 
pTRE-2Hyg vector  
 1&2 
(Table 2.4) 
Produced during 
this work  
2 LATS1-mut-
pTRE2hyg 
Produced by Mutagenesis of 
expression construct 1 
1&2 
(Table 2.4) 
Produced during 
this work 
4.1.1.4.4 Centromere probes  
All FISH probes were received from Prof. A. Jauch, Department of Human Genetics, 
University of Heidelberg, Germany. 
Table 4.6: Centromere probes used for FISH 
 
 
 
 
 
 
 
 
 
4.1.1.4.5 Nucleotides 
Table 4.7: Nucleotides and DNA 
Chromosome Probe Name Resistance 
Chr 1 pUC 1.77 Ampicillin 
Chr 2 pBS4D (M. Rocchi) Ampicillin 
Chr 3 pAE0.68 (M. Rocchi) Ampicillin 
Chr 8 pZ8.4 Ampicillin 
Chr 17 P17H8 Ampicillin 
Chr 20 pZ20 (M. Rocchi) Ampicillin 
Name Source 
CY3-dUTP Dyomics GmbH, Jena, Germany 
FITC-dUTP Dyomics GmbH, Jena, Germany 
dNTPs in Lithium salt Roche Diagnostics, Basel, Switzerland 
Salmon Sperm DNA Sigma Aldrich St. Louis, USA 
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4.1.1.5 Antibodies 
4.1.1.5.1 Primary Antibodies 
Table 4.8: List of Primary Antibodies 
Antigen Clone Immunized 
species/Typ 
Dilution Fixation 
for IF 
Source 
Actin sc-
47778 
Mouse 
(monoclonal) 
1:5000 - Santa Cruz, 
Dallas, USA 
CP110 1278 Rabbit 
(ployclonal) 
1:200 MeOH/
Ac 
Proteintech, 
Chicago, USA 
CREST -
Centromere 
Z140228
B2 
Human 1:20 MeOH EuroImmun, 
Germany 
IgG mouse SC-2025 Mouse 1:200 - Santa Cruz, 
Dallas, USA 
IgG Rabbit SC-2027 Rabbit 1:200 - Santa Cruz, 
Dallas, USA 
LATS1 C665B Rabbit 
(monoclonal) 
1:1000 MeOH/
Ac 
Cell Signalling, 
MA, USA 
MCM7 141.2, 
sc-9966 
Mouse 
(monoclonal) 
1:1000 - Santa Cruz, 
Dallas, USA 
Pericentrin ab4448 Rabbit 
(polyclonal) 
1:1000 MeOH Abcam, 
Cambridge, UK 
pYAP1 
(S127)  
EP1675
Y 
Rabbit 1:10000 - Abcam, 
Cambridge, UK 
YAP1 EP1674
Y 
Rabbit 1: 
25000 
MeOH Abcam 
Cambridge, UK 
YAP1 (63.7) Sc-
101199 
Mouse 1:1000 MeOH Santa Cruz, 
Dallas, USA 
γ-Tubulin TU-30 Mouse 
(monoclonal) 
1:1000 MeOH/
Ac 
EXBIO, 
Prag, CZ 
α-Tubulin DM1A Mouse 
(monoclonal) 
1:500 MeOH/
Ac 
Sigma-Aldrich 
St. Louis, USA 
4.1.1.5.2 Secondary Antibodies 
Table 4.9: List of Secondary Antibodies 
Antigen Immunized 
species 
Conjugate Dilution Source 
Anti-
MouseHRP 
Goat HRP 1:5000 Santa Cruz, Dallas, USA 
Anti- rabbit 
HRP 
Goat HRP 1:5000 Santa Cruz, Dallas, USA 
Mouse IgG Goat Alexa 568 1:1000 Invitrogen, Carlsbad, 
USA 
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Mouse IgG Goat Alexa 488 1:1000 Invitrogen, Carlsbad, 
USA 
Rabbit  IgG Goat Alexa 568 1:1000 Invitrogen, Carlsbad, 
USA 
Rabbit IgG Goat Alexa 488 1:1000 Invitrogen, Carlsbad, 
USA 
4.1.1.6 Enzymes 
Table 4.10: List of Enzymes 
Name Source 
DNAse Roche Diagnostics, 
Basel, Switzerland 
E.coli DNA Polymerase I Roche Diagnostics, 
Basel, Switzerland 
Pepsin Sigma-Aldrich, 
Missouri, USA 
Phusion High-Fidelity DNA Polymerase Fermentas/Thermo Fisher Scientific, 
Waltham, USA 
Restriction Endonucleases New England Biolabs,  
Ipswich, UK 
RNase Roche Diagnostics, 
Basel, Switzerland 
Shrimp Alkaline Phosphatase Fermentas/Thermo Fisher Scientific, 
Waltham, USA 
T4 DNA Ligase  New England Biolabs,  
Ipswich, UK 
Lambda phosphatase New England Biolabs,  
Ipswich, UK 
 
4.1.2 Molecular weight markers 
Table 4.11: Molecular Weight Markers  
 
 
 
Name Source 
HighRanger DNA Ladder Norgen Biotek Corp., Ontario, Canada 
Hind III marker Fermentas Life Science,  Waltham, USA 
Precision Plus ProteinTM Dual Color 
Standards 
Bio-Rad Laboratories, Hercules, USA 
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4.1.3 Kits 
Table 4.12: Kits used in this work 
Name Source 
Annexin V FITC v1.0  BD Bioscience, San Jose, USA 
CellTiter-Glo® Luminescent Viability Assay Promega, Madison, USA 
Fugene® 6 Transfection Reagent Promega, Madison, USA 
In-Fusion® HD Cloning Kit  Clontech Inc., Mountain View, CA 
Midi/Maxi Plasmid Purification Kit Qiagen, Hilden, Germany 
Pierce® ECL Western Blotting Substrate Thermo Scientific, Waltham, USA 
QIAprep® Spin Miniprep Kit Qiagen, Hilden, Germany 
QIAQuick® Gel Extraction Kit Qiagen, Hilden, Germany 
Quick StartTM Bradford Protein Assay Bio-Rad Laboratories, Hercules, USA 
QuikChange XL Mutagenesis Kit Agilent Technologies, Santa Clara, USA 
Vectashield® Vector Laboratories, Burlingame, USA 
Vectashield® with DAPI Vector Laboratories, Burlingame, USA 
 
 
4.1.4 Chemicals  
The standard chemicals used in this work were purchased from Sigma-Aldrich (St. Louis, 
USA), Carl Roth GmbH (Karlsruhe, Germany), Merck (Darmstadt, Germany), Roche (Basel, 
CH), AppliChem (Darmstadt, Germany), Serva (Heidelberg, Germany) and GERBU 
Biochemicals GmbH (Gaiberg, Germany). Consumables used were purchased from GE 
Healthcare (Chalfont St Giles, UK), Greiner Bio-One (Kremsmuenster, Austria), Starlab 
(Hamburg, Germany), Sarstedt (Nuembrecht, Germany), Eppendorf (Hamburg, Germany) 
and Whatman (Maidstone, UK).  
4.1.4.1 Media, buffers and solutions 
4.1.4.1.1 Media for Bacterial culture 
LB-Medium 1% (w/v) Trypton  
0,5% (w/v) Yeast extract  
1% (w/v) NaCl  
pH 7,2 
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LB-Agar LB-Medium  
1,5% (w/v) Agar 
SOC-Medium 2% (w/v) Trypton  
0,5% (w/v) Yeast Extract 
0,05% (w/v) NaCl  
2,5 mM KCl  
10 mM MgCl2  
20 mM Glucose  
pH 7,0 
 
4.1.4.1.2 Media and solutions for cell culture 
DMEM Gibco®/Invitrogen, Carlsbad, USA 
McCoy´s 5A Gibco®/Invitrogen, Carlsbad, USA 
OptiMEM Gibco®/Invitrogen, Carlsbad, USA 
B-Mercaptoethanol Gibco®/Invitrogen, Carlsbad, USA 
PBS/EDTA 2 mM EDTA in PBS 
Poly-L-Lysine Sigma-Aldrich St. Louis, USA 
Trypsin/EDTA-Lösung 0,25% (v/v) Pig-trypsin (Gibco®/Invitrogen, Carlsbad, 
USA) in PBS/EDTA 
 
4.1.4.2 Buffers and reagents 
 
Acrylamide Acrylamid / Bis 37.5:1 solution (30% w/v) 
(Serva Electrophoresis, Gremany) 
APS Carl Roth, GmbH, Germany 
Blocking buffer for 
Immunofluorescence 
10% Goat serum in PBS  
Blocking buffer for 
Western Blot 
5% Bovine serum albumin (BSA) in TBST 
Borat Buffer 20 mM boric acid  
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1,3 mM EDTA  
pH 8.8 
Dilution Buffer for CoIP 10 mM Tris/HCl, pH 7.5  
150 mM NaCl  
0.5 mM EDTA  
1 Tablet/50 ml Complete Protease inhibitor  
(Roche, Basel, CH) 
Hoechst 33342 Trihydrocloride, trihydrate 
(Life Technologies) 
PBS 137 mM NaCl  
2,7 mM KCl  
10 mM Na2HPO4  
1,7 mM KH2PO4  
pH 7,4 
RIPA-Buffer 50 mM Tris/HCl, pH 7,5  
150 mM NaCl  
0.25 % (w/v) Nadeoxycholate  
1 % (v/v) Nonidet P40  
1 mM EDTA  
1 Tablets/50 ml Complete protease inhibitor  
(Roche, Basel, CH)  
5 Tablets/50 ml PhosSTOP Phosphatase inhibitor 
(Roche, Basel, Switzerland) 
SDS 20% Dissolved in water to make 20% solution 
(Roth) 
SDS-Running buffer 380 mM glycin  
50 mM Tris  
0,1% (w/v) SDS 
SSC 20x 3M NaCl 
0.3M Trisodium citrate  
pH 7.0 
Stop Mix 0.5% Dextran blue 
0.1% NaCl 
20mM EDTA 
20mM Tris pH7.5, in double distilled water 
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TAE 40 mM Tris/HCl, pH 8,0  
0,12% conc. Acetic acid  
1 mM EDTA 
TEMED Serva Electrophoresis, Germany 
TBS 10 mM Tris/HCl  
150 mM NaCl  
pH 8.0 
TBST 0.1% (v/v) Tween 20 in TBS 
Transfer buffer 10x  50 mM Tris  
40mM Glycine  
3.7g SDS 
(For working solution add 20% of absolute methanol 
to 1x transfer buffer)  
6x DNA-Loading Buffer 200 mM EDTA  
100 mM Tris/HCl, pH 7,5  
0,01% (w/v) Bromphenol blue  
0,01% (w/v) Xylencyanol  
30% (v/v) Glycerol 
6x SDS-Protein loading 
buffer 
240 mM Tris/HCl, pH 6,8  
30% (v/v) β-Mercaptoethanol  
6% (w/v) SDS  
30% (v/v) Glycerol  
0,002% (w/v) Bromphenolblau 
Vectashield Mounting Medium  
(Linaris GmBH, Germany) 
 
4.1.4.3 Antibiotics 
Carbenicillin Serva, Heidelberg, DE,  
Final concentration: 100 μg/ml 
Geneticin (G418) PAA Laboratories GmbH (Austria)  
Final concentration: suited for the cell line  
Hygromycin B Invitrogen, Carlsbad, USA, 
Final concentration: suited for the cell line  
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Penicillin/Streptomycin Gibco®/Invitrogen, Carlsbad, USA,  
Final concentration: 100 μg/ml 
Puromycin Merck, Darmstadt, DE, Final concentration: suited for 
the cell line 
 
4.1.4.4 Drugs 
Nocodazole Sigma-Aldrich, Missouri, USA 
Thymidine Sigma-Aldrich, Missouri, USA 
Verteporfin Sigma-Aldrich, Missouri, USA 
 
4.1.4.5 Laboratory equipment 
BD Accuri C6 Flow cytometer Becton Dickinson, San Jose, 
USA 
Centrifuge 5417R Eppendorf, Hamburg, Germany 
Fluorescence microscope Axiovert 200M 
equipped with AxioCam MRm 
Carl Zeiss, Göttingen, Germany 
Fluorescence microscope Axioskop equipped 
with AxioCam MRc 
Carl Zeiss, Göttingen, Germany 
Axio Observer.Z1, Live cell observer  Carl Zeiss, Göttingen, Germany 
Confocal  Microscope Leica TCS SP5 Leica, Wetzlar, Germany 
Mini-PROTEAN® Tetra Cell Bio-Rad Laboratories, Hercules, 
USA 
Mini Trans-Blot® Electrophoretic Transfer Cell Bio-Rad Laboratories, Hercules, 
USA 
PCR-Maschine „Mastercycler gradient“ Eppendorf, Hamburg, Germany 
PCR-Maschine „Mastercycler personal“ Eppendorf, Hamburg, Germany 
pH-Meter SevenMulti Mettler Toledo, Giessen, 
Germany 
Photometer Eppendorf, Hamburg, Germany 
Shandon Cytospin III  Thermo electron corporation, 
Pittsburg, USA 
Spectrophotometer “NanoDrop” PeqLab Biotechnologie, 
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Erlangen, Germany 
UV Table Konra Benda, Wiesloch, 
Germany 
Zentrifuge Megafuge 1.0R Heraeus, Hanau, Germany 
Zentrifuge Sorvall RC6Plus Thermo Scientific, Waltham, 
USA 
 
4.1.4.6 Software 
ApE- A plasmid editor M. Davis Wayne, Utah, USA 
AxioVision Version 4.7.2 Carl Zeiss, Göttingen, Germany 
BD Accuri C6 Becton Dickinson, San Jose, USA 
ImageJ Wayne Rasband, USA 
Microsoft Office 2010 Microsoft Corporation, Redmond, USA 
QuickChange Primer Design  Stratagene, LaJolla, USA 
 
4.2 Methods 
4.2.1 Cell biology methods 
4.2.1.1 Cell culture 
The cell lines listed in Table 4.1 were cultured at 37 °C under 5% CO2 in tissue culture flasks 
or dishes. To passage, adherent cells were washed once with PBS/EDTA, trypsin/EDTA was 
added and the cells were incubated for 2-4 min at 37 °C. The cells were then collected in 
fresh medium, and seeded into new cell culture flasks or dishes. The following media were 
used: 
Normal Human 
Astrocytes 
HA medium + 10% (v/v) FCS + 1% Pen/Strep 
NCH149 DMEM + 10% (v/v) FCS + 1% Pen/Strep 
NCH82 DMEM + 10% (v/v) FCS + 1% Pen/Strep 
U2OS DMEM + 10% (v/v) FCS + 1% Pen/Strep 
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U2OS-Tet on DMEM + 10% (v/v) FCS + 1% Pen/Strep + 4mM 
Glutamine + Geneticine (End concentration 200ug/ml) 
 
 
4.2.1.2 Synchronization of human cell lines  
In order to study cell cycle duration and progression, cells were synchronized using one of 
the following methods: 
4.2.1.2.1 Nocodazole 
Cells were incubated for about 16 h with 100 ng/ml nocodazole to block asynchronously 
growing cells in early mitosis. After this incubation, cells were gently washed twice with 
nocodazole-free medium and mitotic cells were collected by mitotic “shake off”, i.e., 
strongly tapping the flasks to detach rounded mitotic cells from the bottom. If mitotic cells 
were needed, these cells were washed (5 minutes, 200 g, RT) and then fixed for FACS (ice 
cold 100% methanol) or lysates were prepared for Western blot or CoIP experiments (see 
4.2.6). To analyze later cell cycle stages, mitotic cells were seeded in medium without 
nocodazole and incubated for the appropriate time. 
4.2.1.2.2 Synchronization by double thymidine block  
200,000 cells were seeded in 14 cell culture dishes (60 mm). At the next day the first 
thymidine block was performed by incubating the cells with medium containing 2 mM 
thymidine for 16 hours leading to S-phase arrest of the cells. After washing three times with 
PBS, medium containing 24 uM 2'-deoxycytidine was added to the cells and they were 
incubated at 37 °C for additional 12 hours. Then, the cells were subjected to the second S-
phase arrest by re-addition of 2 mM thymidine containing medium for 12 hours. After 
washing three times with PBS, 2'-deoxycytidine-containing medium was added to the cells 
and processed every hour to obtain lysates upto 8 hours. 
4.2.1.3 Poly-l-lysine coating 
Sterile glass slides and cover slips were coated with poly-l-lysine solution under sterile 
conditions, incubated for 20 minutes at 37°C and then washed twice with 1x PBS. Coated 
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slides and coverslips were used for culturing cells in order to enhance the attachment of 
cells, especially mitotic cells, to glass slides or cover slips. 
4.2.2 Immunofluorescence 
To stain eukaryotic cells by indirect immunofluorescence, cells were cultured on coverslips. 
The cells were washed with PBS and fixed in accordance with the requirements of the 
primary antibodies used for staining (see Table 4.8). For methanol-acetone fixation the cells 
were incubated with a 1:1 methanol-acetone mixture for 7 minutes and the coverslips were 
then air dried. For methanol fixation, cells were incubated for 10 minutes with ice-cold 
100% methanol followed by air drying. The dried coverslips were stored at -20 °C. After 
fixation, the cells were blocked for 30 minutes with 10% goat serum in PBS and then 
incubated with the primary antibody for 1-1.5 hours. The cells were washed 3 times with 
PBS to remove excess primary antobody and then incubated for 30 minutes with the 
secondary antibody. Both primary and secondary antibodies were diluted in 10% goat 
serum in PBS (see Tables 4.8 and 4.9). To stain the nuclei, cells were then incubated with 10 
ug/ml Hoechst 33342 in 10% goat serum in PBS and incubated for 5 min. After washing 
three times with PBS and washing once with ddH2O, the coverslips were immersed in 100% 
ethanol, dried on filter paper and coated with Vectashield. The analysis of stained cells was 
done by fluorescence microscopy. 
4.2.3 Flow cytometry 
The distribution of cells from a cell population in different cell cycle phases was determined 
using flow cytometry. For this, cells were collected by trypsinization or mitotic shake off and 
washed with PBS. Subsequently, the cell pellet was resuspended in 250 ul PBS. The cells 
were fixed by dropwise addition of 700 ul of 100% ice-cold methanol and vortexing. After 
incubation at 4°C for at least 1 hour the cells were washed once with PBS and 200 ul of a 
propidium iodide solution (10 ug/ml propidium iodide + 0.25 mg/ml RNase A in PBS) was 
added to the cells. Cells were then incubated for 30 min at 37 °C and analyzed by a BD 
Accuri flow cytometer using C6 software. Since propidium iodide is a DNA intercalating 
substance, DNA content and the cell cycle stages can be determined. 
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4.2.4 Live cell imaging 
In order to observe the behavior of cells in real time, live cell imaging was performed. For 
this purpose, cells were seeded in 35 mm dishes (μ-dish, Ibidi, Martinsried) and allowed to 
adhere for 24 hours. Cells were syncronized overnight (see 4.2.1.2), released and placed 
into the incubation chamber (37°C and 5% CO2) of an Axio Observer. To determine the 
duration of mitosis, bright field images were taken every 10 minutes at various dish 
positions using a 20x objective. 
4.2.5 Protein biochemistry methods 
4.2.5.1 Preparation of cell lysates  
 
The preparation of cell lysates was carried out using RIPA buffer. Adherent cells were 
scraped from the bottom of the cell culture dishes, washed with PBS. Cells were pelleted by 
centrifugation. The pellet was resuspended in RIPA buffer and incubated on ice for at least 
30 minutes. Cell clumps were removed by repeated pipetting up and down or vortexing 
during the incubation period. The mixture was then subjected to centrifugation for 10 
minutes at 18000 g and 4 °C, the supernatant was transferred to a new tube and the protein 
concentration was determined (see 4.2.5.2.) and analyzed either by SDS-PAGE (see 4.2.5.3.) 
or used for co-immunoprecipitation (see 4.2.6). 
4.2.5.2 Determination of protein concentration  
 
To determine the protein concentration of cell lysates the "Quick START Bradford Protein 
Assay" was used according to the manufacturers protocol. To create a calibration curve a 
BSA standard was used. 
4.2.5.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The electrophoretic separation of proteins was performed by SDS polyacrylamide gel 
electrophoresis under denaturing conditions (90). Gels were prepared with 6-12% 
acrylamide depending on the size of the proteins to be detected. Cell lysates were mixed 
with 1x SDS protein loading buffer, boiled for 5 min at 95 °C and 50-100 ug protein was 
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loaded per well. Separation was performed in the stacking gel at 80 V and in the separating 
gel at 110-120 V. 
4.2.5.4 Western Blot 
Proteins separated by SDS-PAGE (see 4.2.5.3.) were transferred to a PVDF membrane (GE 
Healthcare, Chalfont St Giles, UK) by wet transfer methodology using "Mini Trans-Blot 
Electrophoretic Transfer Cell". The membrane was activated in 100% methanol for 1 minute, 
and sandwiched with the gel between 3 layers of filter paper and fiber pads on each side. 
The protein transfer was performed for 2.5 hours at 4 °C and 450 mA in either borate buffer 
or methanol transfer buffer. The proteins were then detected by immunodetection (see 
4.2.5.5).  
4.2.5.5 Immunodetection 
For the detection of proteins by means of immunodetection the membrane was blocked for 
one hour with 5% (w/v) milk powder in 1x TBST at room temperature and then incubated 
with the primary antibodies overnight at 4 °C with gentle shaking. After three 5 minutes 
washes with 1 x TBST, the membrane was incubated with secondary antibody for 1 hour at 
room temperature and then again washed 3 times for 5 minutes each with 1 x TBST. Both 
primary and secondary antibodies were diluted in 5% (w/v) milk powder or 5% (w/v) BSA in 
1 × TBST (see Tables 4.8 and 4.9). Detection was done by treating the membrane with 
"Pierce ECL Western Blotting Substrates" according to the manufacturer's instructions 
followed by exposure to X-ray films (Amersham HyperfilmTM ECL, GE Healthcare, Chalfont 
St Giles, UK). The films were then developed in a dark room. 
4.2.6 Co-Immunoprecipitation 
To detect protein-protein interactions, co-immunoprecipitation (Co-IP) was performed in 
which an antibody against the target protein was used. By adding this antibody to whole cell 
lysates, proteins binding to the target protein or proteins present in the same complex, can 
be co-immunoprecipitated with the target protein. For this purpose, cell lysates were 
prepared (see 4.2.5.1.) and diluted with 500 ul of dilution buffer. For the co-
immunoprecipitation of endogenous proteins the antibodies were bound to protein A/G 
agarose beads. For this, 25 µl of each, protein A and protein G agarose beads (Roche, 
Basel, Switzerland), were mixed and washed three times with 500 µl dilution buffer 
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(centrifugation at 500 g, 4 °C for 5 min) and incubated with 1 µg antibody for one hour under 
constant rotation at 4 °C. The IgG antibodies are used as control. The cell lysates were 
incubated with the antibody-coupled agarose beads overnight at 4 °C with continuous 
rotation. The agarose were again washed three times with dilution buffer, mixed with 2x 
SDS protein loading buffer and boiled for 10 minutes at 95 °C. The analysis was performed 
by SDS-PAGE (see 4.2.5.3.), Western blot (see 4.2.5.4.) and immunodetection (see 4.2.5.5.).  
4.2.7 Molecular Biology Methods 
4.2.7.1 PCR 
Polymerase chain reaction (PCR) was performed to enzymatically amplify specific DNA 
sequences using suitable primers (Table 4.3) (91). To this end, a PCR approach was 
established, as follows: 
CloneAmp HiFi PCR Premix  10 µl 
Forward primer (100pmol/µl) 1 µl 
Reverse primer (100pmol/µl) 1 µl 
dNTP mix (10 mM each) 1 µl 
Template DNA 10 ng 
Nuclease free water make up to 50 µl 
 
The PCR program was set as follows; denaturation, annealing and elongation were repeated 
for 35 cycles: 
 
Initial denaturation of DNA 98 °C 10 s 
Denaturation and Annealing 55 °C 15 s 
Elongation 72 °C 5 s per kb of template 
 
The PCR product was treated with DpnI enzyme in Super Cut buffer for 1 hour at 37 °C to 
remove the template DNA, followed by heat treatment at 80 °C for 15 minutes to inactivate 
the enzyme. The purification of amplified DNA fragments was carried out using the 
"QIAQuick Gel Extraction Kit" according to the manufacturer’s protocol. 
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4.2.7.2 Agarose gel electrophoresis  
 
DNA fragments were separated according to their size using agarose gel electrophoresis. 
The DNA samples were mixed with 1x DNA loading buffer and loaded on to 1% agarose 
gels containing ethidium bromide (0.1 µl/ml of a 1% ethidium bromide solution). The 
electrophoresis was carried out in 1x TAE buffer for 1 hour at 120 V. 
4.2.7.3 DNA digestion by restriction endonucleases 
  
Plasmid DNA was cut by type II restriction endonucleases at specific sites. Two batches of 
50 ul reactions were prepared containing the following components:  
10x reaction buffer 5 µl  
Restriction enzymes 20 U per enzyme  
Purified PCR fragment or plasmid DNA 5 ng / 5 µg 
nuclease-free water make up to 50 µl 
 
The mixtures were incubated for 1-3 h at 37 °C. The linearized plasmid DNA was 
dephosphorylated by the addition of 1 U "Shrimp Alkaline Phosphatase" for 30 min at 37 °C. 
Purification of cleaved DNA was performed by "QIAQuick Gel Extraction Kit" according to 
the maufacturer’s protocol. 
4.2.7.4 Ligation 
 
After determination of the concentration of the PCR amplified DNA and the target plasmid, 
the ligation was carried out using the manufacturer’s protocol (In-Fusion HD Cloning Kit). 
Ligation mixture was prepared along with negative control (without PCR amplified DNA) as 
follows: 
 
 
 
The ligation was performed for 15 minutes at 50 °C.  
5x HD enzyme mix 2 µl 
Vector (54 ng)  2 µl 
PCR amplified DNA (50 ng)  4 µl   
Nuclease free water 2 µl  (to make up to 10 µl ) 
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4.2.7.5 Transformation of chemically competent bacteria 
To transform chemically competent bacteria (see Table 4.2), 50 ul of competent bacteria 
provided with the In-Fusion HD Cloning Kit were thawed and incubated with 2.5 ul of 
ligation mixture for 30 minutes on ice. This was followed by a heat shock for 45 s at 42 °C. 
After incubation for 2 minutes on ice, 500 ul of SOC medium was added and the bacteria 
were allowed to grow for 1 hour at 37 °C while shaking. Then, bacteria were centrifuged (5 
minutes, 1300 g), resuspended in 100 ul of SOC medium and streaked on LB plates 
containing the respective antibiotic. Incubation was carried out overnight at 37 °C. 
4.2.7.6 Mutagenesis 
Site-directed mutagenesis was carried out using mutagenesis primers listed in Table 4.3 
and the "QuikChange II XL Site-Directed Mutagenesis Kit" according to the manufacturer's 
instructions. The mutagenesis was performed using the following PCR program. 
Denaturation, annealing and elongation were repeated for 35 cycles:  
Initial denaturation  95°C 2mins 
Denaturation 95°C 20 s 
Annealing 60°C 10 s 
Elongation 68°C 30 s per kb 
Final Elongation 68°C 5 mins 
 
The PCR product obtained was treated with Dpn I enzyme and transformed into chemically 
competent bacteria (see 4.2.7.5). These bacteria were plated on ampicillin agar plates and 
resistant colonies were picked. The DNA was extracted using miniprep kit (see 4.2.7.7) and 
the presence of the mutation was verified by sequencing (GATC Biotech AG, Konstanz, 
Germany). 
4.2.7.7 Plasmid isolation  
 
For the extraction of plasmid DNA, single colonies were picked and placed in 2 ml LB 
medium containing the appropriate antibiotic and incubated overnight at 37 °C while 
shaking. The next day, plasmid DNA was purified using the "QIAprep Spin Miniprep Kit" 
according to manufacturer's instructions. Verification of successful cloning was carried out 
by sequencing (GATC Biotech AG, Konstanz, Germany). For purification of larger amounts 
of plasmid DNA, the positive clones were expanded into 100 ml of LB medium with 
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antibiotic and subsequent DNA purification by the "Midi/Maxi Plasmid Purification Kit" 
according to the manufacturer's protocol. 
4.2.8 Transfection of human cell lines 
4.2.8.1 Transient transfection 
To study phenotypes after overexpression of a protein, plasmid DNA was transfected into 
human cells. For transfection of plasmid DNA Fugene 6 was used according to the 
manufacturer's instructions. The ratio of transfection reagent (µl): plasmid (µg) used was 
either 3:1. The cells were seeded one day before transfection so that 60% confluency was 
attained on the day of transfection. 
4.2.8.2 Stable transfection  
For the preparation of stably transfected cell lines, the cells were transfected with the 
appropriate expression construct (Table 4.5) and incubated at 5% CO2 for 48 hours at 37 
°C. For selection and isolation of the transfected cells, these were re-plated at various 
dilutions in larger cell culture dishes and the antibiotic whose resistance gene was included 
in the plasmid DNA, was added to the culture medium. The cells were cultured for two to 
three weeks and the medium with antibiotic was changed every two days. During this 
selection period, single colonies were scraped off carefully using a pipette tip and put into a 
24-well plate, seeding only one colony per well. The cells were expanded and the success 
of the stable transfection was determined by indirect immunofluorescence (see 4.2.2) and 
Western blotting (see 4.2.5). 
4.2.9 Cytogenetic methods  
4.2.9.1 Multicolour FISH and karyotyping 
Multiplex fluorescence in situ hybridization (M-FISH) on fixed metaphase spreads of the 
GBM cell lines NCH82 and NCH149 were carried out as described (92). For this, DOP-PCR 
amplified probe pools were labeled in combination with seven different fluorochromes 
(DEAC, FITC, Cy3, Cy3.5, Cy5, Cy5.5, and Cy7) and hybridized together in the presence of 
cot-1 DNA. Twenty-one metaphase spreads were captured using a DM RXA 
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epifluorescence microscope (Leica Microsystems, Bensheim, Germany) equipped with a 
Sensys CCD camera (Photometrics, Tucson, AZ, USA). Images were processed on the 
basis of the Leica MCK software (Leica Microsystems Imaging solutions, Cambridge, UK) 
and presented as multicolor karyograms. These experiments were performed by Brigitte 
Scholer in the laboratory of Prof. A Jauch, Department of Human Genetics, University of 
Heidelberg. 
4.2.9.2 Interphase FISH 
Two color FISH experiments were carried out according to previously reported standard 
protocols (93) using repetitive DNA probe sets for the centromeric regions of chromosomes 
(see Table 4.6) and atleast 300 nuclei per experiment were analyzed for each chromosome. 
4.2.9.2.1 Nick translation 
For direct labeling of centromere repetitive probes, a nick translation reaction was 
performed as follows: 
B-mercaptoethanol  5 µl 
NT-Buffer (10x) 5 µl 
dNTP mix (mM) 5 µl 
Probe DNA 1 µg 
dUTP ( Spectrum green/orange) 1 µl 
DNAse 1mg/ml (1:50 in water) 3 µl  
DNA polymerase (50 U/µl) 1 µl 
Nuclease free water  up to 50 µl 
 
The reaction mixture was incubated for 90 minutes at 15 °C. A stop mix was added to the 
tubes to block the polymerase and stop the reaction. The size of the probes was checked 
by agarose gel electrophoresis (see 4.2.7.2) using Hind III marker as molecular weight 
marker. 
4.2.9.2.2 Precipitation of probes and preparation of the hybridization mix 
The labeled probes were precipitated by spinning at 10000 g for 30 minutes at 4 °C. To 
make the hybridization mix ready to use, the pellet was re-suspended in 6.5 ul of deionized 
formamide by shaking at 37 °C followed by addition of 3.5 ul of 20% dextran sulphate. 
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4.2.9.2.3 Hybridization 
The desired cells were collected, washed, put on glass slides using a cytospin centrifuge 
(400 g, 5 minutes) and fixed using methanol-acetic acid (3:1). The slides were be stored at -
20 °C up to several days. For hybridization, the slides were equilibrated briefly in a coplin jar 
with 2x SSC at 37 °C. Then, the slides were incubated for 1 hour with 100 mg/ml (1:200 ul 
2x SSC) RNase in a moist chamber at 37 °C. Slides were washed three times with 2x SSC 
for 5 minutes and then treated with pepsin HCL working solution in a coplin jar for 12 
minutes. The slides were subsequently washed with 1x PBS and fixed with 1% 
formaldehyde at RT for 10 minutes under a fume hood. For denaturation, the slides were 
immersed in 70%, 90% and 100% ethanol sequentially for 3 minutes each. For 
hybridization, 3 µl of hybridization mix (see 4.2.9.2.2) was added to each cytospin and 
covered with a coverslip. Then, slides were placed in a metal box and incubated in a water 
bath for 5 minutes at 75 °C. The coverslips were sealed to prevent them from drying and 
incubated overnight at 37 °C. At the next morning coverslips were removed and the slides 
were washed twice with 0.2x SSC and once with 4x SSC/1% Tween 20. DAPI was added to 
the cytospins to stain the DNA and cells were mounted using Anti-Fade. Analysis was 
performed using fluorescence microscopy.  
4.2.10  Whole exome sequencing 
Dr. Balca Mardin, a member of Jan Korbel’s group (Genome biology) at EMBL, Heidelberg, 
Germany performed whole exome sequencing of the NCH149 cell line as well as of the 
control and tumor DNA from the patient of whom the cell line was established. 
4.2.11 Sanger sequencing 
LATS1 mutation in genomic DNA of cell lines were confirmed by Sanger sequencing. For 
this, mRNA was isolated and cDNA was synthesized followed by PCR amplification of 
LATS1 mutation containing region using the primers 5 and 6 in table 4.3. The PCR products 
along with primer 7 (table 4.3) were then sent for Sanger sequencing to GATC. 
                                                                                                               Materials and Methods 
 44 
4.2.12  Viability assay 
Viability assay was performed to calculate the number of viable cells in culture with and with 
out verteporfin treatment. For this assay, the cells were seeded in 6-well plates (1x10E6 
cells per well) and allowed to adhere over night. The next day, desired concentrations of the 
drug to be analyzed were prepared and added to the cells. At desired time points after 
addition of the drug, cells were harvested and the number of live cells were counted.  
4.2.13 Annexin staining 
FITC Annexin V is used to quantitatively determine the percentage of cells within a 
population that are undergoing apoptosis. Annexin V is a calcium-dependent phospholipid-
binding protein that has a high affinity for phosphatidylserine (PS), which is found exposed 
in apoptotic cells. Propidium Iodide (PI) is a standard flow cytometric viability probe and is 
used to distinguish viable from nonviable cells. Viable cells with intact membranes exclude 
PI, whereas the membranes of dead and damaged cells are permeable to PI. Cells that stain 
positive for FITC Annexin V and negative for PI are currently undergoing apoptosis. Cells 
that stain positive for both FITC Annexin V and PI are either in the end stages of apoptosis, 
are undergoing necrosis, or are already dead. Cells that stain negative for both FITC 
Annexin V and PI are alive and not undergoing measurable apoptosis. Treated and 
untreated cells were harvested, washed twice with ice cold PBS and then resuspend in 1× 
binding buffer at a concentration of 1 × 106 cells/ml). Then 100 μl of this solution (1 × 105 
cells) was transfered to a 5 ml culture tube followed by addition of 5 μl of FITC Annexin V 
and 10 μl PI, vortexed and incubated for 15 minutes at 25 °C in the dark. Unstained and 
single stained controls for each sample were also prepared for flow cytometric analysis. 
Flow cytometric analysis was performed using a BD Accuri flow cytometer and analysed 
using B6 software. 
4.2.14 Statistical Analysis 
All results are presented as mean ± standard deviation (SD). Differences between 
experimental groups were analyzed by unpaired Student’s t-test for unpaired groups and 
values of p < 0.05 were considered as statistically significant. The asterisks represent 
significantly different values. *: p<0.05; **: p<0.01; ***: p<0.001.  
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5 Results 
5.1 Identification of CIN in glioblastoma cell lines  
5.1.1 Karyoptypic profiling of NCH149 and NCH82 cell  
Cellular genome integrity at the chromosomal level is reflected through cellular ploidy levels 
and intercellular heterogeneity. In order to characterize genome integrity of the two 
glioblastoma (GBM) cell lines NCH149 and NCH82, cytogenetic analysis was performed in 
the laboratory of Prof. Dr. Anna Jauch using multiplex FISH (M-FISH; Figure 5.1) as well as 
classical karyotyping.  By M-FISH analysis both numerical and structural chromosomal 
aberrations were observed in these cell lines. Metaphase spreads of the NCH149 cell line 
(n=21) revealed that these cells display extraordinary CIN with a variety of clones having 
different metaphase chromosome numbers ranging from 42 to 129. In contrast to NCH149 
cells, the chromosome number of NCH82 cells has been almost equal within the 
metaphases analyzed showing a tetraploid karyotype in 15 evaluated metaphases. This was 
indicative for a more stable karyotype of NCH82 cells compared to NCH149 cells as 
observed by Dokic et. al. 2014.  
 
Figure 5.1 M-FISH karyoptypes of GBM cell lines 
M-FISH images of NCH149 (A) showing extreme aneuploidy and NCH82 (B) showing a near tetraploid 
karyotype. Modified from Dokic et. al. International Journal of Radiation Biology, 2014, with 
permission. 
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5.1.2 Confirming CIN in NCH149 cells  
In order to verify the M-FISH data I performed interphase-FISH for chromosomes 2 and 20 
and at least 300 interphase cells were scored for each chromosome by Dr. Tilmann 
Bochtler. Analyzing considerably more cells as compared to M-FISH analysis allowed to 
ensure that NCH82 have a more stable karyotype than NCH149 cells. As expected, high 
intercellular variation in chromosome number was observed in NCH149 cells. Quantification 
showed that up to 10 copies of the analyzed chromosomes were present in single cells. In 
addition, grouping the cells according to the chromosome number revealed that each group 
does not comprise of more than 25% of the cells indicating the presence of CIN (Figure 
5.2A). In contrast, In contrast, NCH82 cells were found to have a stable tetraploid karyotype 
with little intercellular variation. In the NCH82 cell line 68% and 79% of cells were tetraploid 
for chromosme 2 and 20, respectively, and the rest mainly diploid meaning that a major 
fraction of the cells were tetraploid at least for these two chromosomes but not 
chromosomaly instable (Figure 5.2 B).Together this shows that, although both cell lines 
harbor numerically aberrant karyotypes, NCH82 cells have a stable near tetraploid karyotype 
while NCH149 cells are chromosomally instable. 
 
Figure 5.2 Interphase FISH score for chromosmes 2 and 20  
Interphase FISH with centromere probes for chromosmes 2 and 20 of the NCH149 cell line showing 
excessive cell-to-cell variation in chromosome numbers (A). NCH82 cells seem to have a major 
tetraploid subclone and a minor subclone which is diploid for chromosomes 2 and 20 (B). 
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5.2 CIN phenotype of NCH149 cells 
Next, I studied the phenotype of NCH149 cells using immunofluorescence microscopy and 
live cell imaging. To further assess the CIN phenotype, we performed immunofluoresence 
and live cell imging experiments to evaluate parameters such as presence of micronuclei, 
lagging chromosmes, centriole amplification and aberrant mitosis that indicate extent of CIN 
in the NCH149 cell line compared to the NCH82 cell line with out CIN.  
5.2.1 Presence of micronuclei  
Firstly, the two cell lines were stained for DNA (Hoechst) and centromeres (CREST) to 
check for the presence of micronuclei (Figure 5.3). For each cell line 300 cells were counted 
in 3 independent experiments. Upon microscopic analysis it was found that 25 ± 1% (mean 
± SD) of NCH149 cells show micronucleus formation. On the other hand, only 2% ± 1%  
(mean ± SD) of NCH82 cells harbor micronuclei (p < 0.001) (Figure 5.3).  
 
  
Figure 5.3 Extensive micronucleus formation in NCH149 cells 
NCH149 and NCH82 cells were stained with DNA dye, Hoechst (blue) and scored for micronuclei 
(indicated by arrows) by fluoresence microscopy showing that NCH149 cells, in contrast to NCH82 
cells, possess micronuclei. Scale bar, 10 µm. 
 
 
 
Ce
lls
 w
ith
 M
icr
on
uc
lei
 (%
)
0%
25%
50%
NCH149 NCH82
***
Ho
ec
hs
t
NCH149 NCH82
                                                                                                                                        Results 
 48 
5.2.2 Occurrence of whole chromosomes in micronuclei  
Further, to determine the contents of micronuclei I stained the NCH149 cells with the 
nuclear lamina marker lamin A in this experiment to investigate whether the DNA is 
surrounded by a nuclear envelop. In addition I again used the CREST-antibody against 
centromeres. The presence of a CREST signal in micronuclei indicates the presence of 
whole chromosomes. Quantification of 300 cells in 3 independent experiments revealed 
that amongst the cells containing micronuclei, 75.15 ± 2.7% (mean ± SD)  of micronuclei 
harbor 1 or 2 centromere (CREST) signals in NCH149 cells (Figure 5.4). Incontrast, in 
NCH82 cells, however, had only 1.33 ± 0.5% (mean ± SD) of micronuclei with CREST 
signals (p < 0.001). This suggests that NCH149 cells missegregate whole chromosomes at 
significantly higher rates as compared to the NCH82 cell line. 
 
Figure 5.4 Presence of whole chromorsomes in micronuclei of NCH149 cells 
Immunofluoresence staining of NCH149 cells with an antibody to lamin A (red) and CREST antibodies 
(green). Most of micronuclei in NCH149 cells were found to contain one or more CREST signals 
confirming the presence of whole chromosomes (indicated by arrows). Inset shows micrunucleus 
with and without CREST signal. Scale bar, 10 µm.  
 
 
 
M
icr
on
uc
lei
 w
ith
 w
ho
le 
Ch
ro
m
os
om
es
0%
50%
100%
NCH149 NCH82
***
CR
ES
T 
/ L
am
in 
A
NCH149
                                                                                                                                        Results 
 49 
5.2.3 Chromosome missegregation in NCH149 cells 
It has been shown that micronucleus formation occurs due to missegregation of 
chromosomes during late mitosis leading to lagging chromosomes resulting in aneuploidy 
and chromosomal instability (94). Hence, we further analysed mitotic missegregation of 
chromosomes in NCH149 and NCH82 cell lines. For this, we synchronized the cells by 
thymidine block and collected mitotic cells by fixing after release (see 4.2.1.2.2).  Mitotic 
cells were stained with CREST antibodies and an antibody to α-tubulin and 100 mitotic cells 
were scored and quantified from 3 different experiments. Interestingly, in 30 ± 2.2% (mean 
± SD) of mitotic NCH149 cells lagging chromosomes were found (Figure 5.5). In NCH82 
cells only very few cells 0.6 ± 0.57% (mean ± SD) containing lagging chromosomes are 
observed  (p < 0.001). 
The lagging chromosome score correlates with the micronuclei score in both the cell lines 
(see 5.2.1). This suggests that the presence of micronuclei is indeed a result of 
chromosomal missegregation events which is more pronounced in NCH149 cells when 
compared to NCH82 cells. 
 
 
 
 
Figure 5.5 Chromosomal missegregation 
Scoring mitotic cells immunostained with  α-tubulin (red) and CREST (green) antibodies as well as 
Hoechst (blue) showed lagging chromosomes in 30% of mitotic NCH149 cells. In NCH82 <1% of 
mitotc cells showed lagging chromosomes. Scale bar, 10 µm. 
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5.2.4 Centriole amplification 
CIN is often associated with and caused by amplified centrosomes/centrioles. Therefore, we 
next determined the centriole content of NCH149 as well as NCH82 cells by 
immunostaining with antibodies against the centriolar proteins centrin and CP110. Counting 
both centrin and CP110 signals in 100 interphase cells in 3 independent experiments 
revealed that 44.3 ± 2.36 % of NCH149 cells possess supernumerary centrioles while this is 
true for only 8 ± 0.82 % (mean ± SD) of NCH82 cells (p < 0.001) (Figure 5.6). Both 
immunostaining and analysis were performed by Anna Cazzola. 
 
 
Figure 5.6 Centriole amplification in NCH149 cells 
Cells were stained with antibodies to centrin (green) and CP110 (red) and Hoechst. Cells with > 4 
centrin signals were considered to have centriole amplification. Centriole amplification was observed 
in 44.3 % of NCH149 cells whereas NCH82 cells show amplified centrioles in only 8% of the cells.  
Scale bar, 10 µm. 
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5.2.5 Mitotic phenotype 
Aberrant multipolar mitoses or evasion from cytokinesis after nuclear division is one of the 
main mechanisms leading to aneuploidy or CIN especially in the presence of supernumerary 
centrosomes. Often in cancer cells the extra chromosomes cluster together to force the cell 
into pseudo-bipolar division. However, despite clustering, extra centrosomes prolong 
mitosis by delaying the satisfaction of the SAC due to merotelic attachment of kinetochores 
to microtubules. To investigate the mitotic phenotype of NCH149 and NCH82 cells 
immunofluorescence microscopy and live cell imaging techniques were used. 
For immunofluorescence microsopy mitotic cells were stained with the centrosomal marker 
pericentrin (PCNT) and α-tubulin to visualise mitotic spindles. Given the aberrant number of 
centrioles, the majority of NCH149 cells surprisingly undergoes bipolar mitosis. Only less 
than 1 of 100 mitoses scored in three independent experiments show abnormal multipolar 
divisions (Figure 5.7A). Also most of the NCH82 cells also undergo bipolar division. 
Further, to analyse the duration of mitosis of NCH149 and NCH82 cells I performed live cell 
imaging. The duration of mitosis was calculated from cell rounding to cytokinesis; n=300; 
(Figure 5.7B). 79% of NCH149 underwent mitosis within 80 minutes compared to 75% of 
NCH82 cells within 40 minutes indicating prolonged mitosis duration in NCH149 cells. In 
addition to the prolonged mitosis, 13 % of mitotic NCH149 cells failed to undergo 
cytokinesis after nuclear division during the 24 hours of observation period. 
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Figure 5.7 Mitotic phenotype  
(A) Immunofluorescence staining of NCH149 and NCH82 cells with antibodies against pericentrin 
(PCNT) (red), α-tubulin (green) and Hoechst shows normal bipolar mitosis in both cell lines. Scale bar, 
10 µm. (B) Duration of mitosis from cell rounding to cytokinesis was calculated from live cell imaging 
data (n=300).  
 
 
Together, these results demonstrate that NCH149 cells missegregate whole chromosomes 
at a high frequency indicated by the presence of whole chromosomes in micronuclei, 
centriole amplification and prolonged mitosis, pointing towards a CIN phenotype of NCH149 
cells. On the other hand NCH82 cells have a stable aneuploid/tetraploid karyotype as they 
show minimal chromosomal missegregation, centriole amplification and normal mitotic 
phenotype. 
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5.3 Mutation profile of NCH149 cells 
To gain insight into the cause of the CIN phenotype of NCH149 cells we performed whole 
exome sequencing of the NCH149 cell line as well as the primary tumor from which the cell 
line was derived, compared to healthy brain tissue (control) of the same patient. Sequencing 
and data analysis was performed by Dr. Balca Mardin form the Korbel group, EMBL, 
Heidleberg. 
5.3.1 Whole exome sequencing  
The read depth plots show massive gains and losses of chromosomes in tumor tissue and 
the cell line derived thereof when compared to control tissue supporting the finding of 
extensive aneuploidy in NCH149 cells (Figure 5.8). 
 
 
Figure 5.8 Read Deapth plots 
Comparative read depth plots of all chromosoms for control, tumor as well as early and late passage 
of the cell line. The red line indicates normal 2n number of chromosmes, copy number gains or 
losses are shown as a shift above or below the red line, respectively. An example for a whole 
chromosome gain of chromosome 7 is highlighted in the blue box. 
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5.3.2 Mutations in NCH149 cells 
Besides gains or losses of whole chromosomes, the whole exome sequencing also led to 
the identification of 24 novel, non-synonymous mutations, found in the primary tumor and 
the derived cell line NCH149 but not in the control healthy brain tissue (Table 5.1).  
Table 5.1 List of Mutant genes in NCH149 
 
 
These mutations are all novel and are predicted to affect protein function. Among the genes 
harboring mutations, LATS1 (highlighted in red) has been chosen for further investigation 
with regard to CIN and tumorigenesis of NCH149 cells since mutations in LATS1 have been 
implicated in tumorigenesis and found to be associated with CIN and resistance to therapy. 
The LATS1 mutation was further verified using Sanger sequencing (Figure 5.9). 
Gene Mutations Zygosity 
ALPK1 exon4:c.184G>A:p.V62M Heterozygous 
C6orf118 exon2:c.158G>A:p.R53Q Heterozygous 
DLGAP3 exon9:c.2618C>T:p.A873V Heterozygous 
DOCK11 exon27:c.2885G>T:p.W962L Homozygous 
DFNB31 exon3:c.863G>A:p.R288Q Heterozygous  
DYRK2 exon3:c.586G>T:p.G196C Heterozygous 
EPHB3 exon4:c.879G>C:p.K293N Heterozygous 
GIPC1 exon3:c.170G>T:p.R57L Heterozygous 
KCNJ12, 18 exon3:c.242G>A:p.R81Q Heterozygous 
KHNYN exon3:c.1262A>C:p.Q421P Heterozygous 
LAMA5 exon69:c.9385G>A:p.G3129S Heterozygous 
LATS1 exon4:c.1843A>G:p.I615V Heterozygous 
LASS3 exon12:c.860C>T:p.T287M Heterozygous 
LILRA3 exon5:c.557C>T:p.A186V 
exon5:c.749C>T:p.A250V 
Heterozygous  
Heterozygous 
LRP2 exon27:c.4493C>T:p.T1498M Heterozygous 
MUC6 exon31:c.4711C>A:p.P1571T Heterozygous 
MMP1 exon7:c.911G>A:p.R304H Homozygous 
OR52K1 exon1:c.59C>G:p.P20R Homozygous 
PIK3R1 exon10:c.1126G>A:p.G376R Heterozygous 
PUM1 exon5:c.720T>A:p.F240L Heterozygous 
PPL exon22:c.4186C>T:p.R1396C Heterozygous 
RANBP17 exon20:c.2144G>A:p.R715H Heterozygous 
SLA exon8:c.602G>T:p.W201L Heterozygous 
SYF2 exon3:c.233A>G:p.E78G 
exon3:c.229T>G:p.W77G 
exon3:c.254A>G:p.K85R 
Heterozygous  
Heterozygous  
Heterozygous 
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5.3.3 LATS1 mutation  
The novel, heterozygous LATS1 mutation identified here is a point mutation (exon 4: base 
1843 A>G) leading to an amino acid exchange p.I615V. This mutation was found to localize 
in the YAP1 binding domain (p.526-p.655) of LATS1 and might therefore might impair 
LATS1 binding to YAP1 (Figure 5.10A). Absence of binding may affect the ability of LATS1 
to phosphorylate YAP1 preventing its cytoplasmic sequestration and subsequent 
degradation.  
To determine the frequency of LATS1 mutations in human cancers we used the online 
database cBioportal (http://www.cbioportal.org/public-portal/). Among all cancers, 10% 
(21/214) of the LATS1 mutations registered in this database were found to be in the YAP1 
binding domain of LATS1 (Figure 5.9B) (95)(96). Also, this data base currently contains 
genomic data from 596 GBM samples. Mutations of LATS1 have been identified in only 1% 
GBM patient samples. The functional significance of the LATS1 mutations in various cancer 
types including GBM is largely unclear. Since LATS1 is part of the Hippo pathway, we 
further investigated the impact of the identified mutation on Hippo pathway signalling. For 
this, we next analyzed expression, localization and interactions of mutated LATS1 and YAP1 
in NCH149 cells. 
 
Figure 5.9 Sanger sequencing of LATS1 in NCH149 and NCH82 cells   
Verification of a LATS1 gene mutation in NCH149 cells compared with wildtype LATS1 in NCH82 
cells by Sanger sequencing, confirming a point mutation at base 1843 A>G leading to an amino acid 
change from isoleucine (GTT) to valine (ATT) (p.I615V). 
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Figure 5.10 Domain structure of LATS1 and LATS1 mutations described up to date 
LATS1 protein domain structure, showing the localization of the I615V mutation in the YAP1 binding 
domain (A). Mutations found in various regions of the LATS1 protein among the GBM data set in 
cBioportal. The pins indicate the positions of mutations and the height of pins their frequency of 
occurance (cBioportal, B). 
5.4 Hippo pathway signalling dysfunction due to LATS1 mutation 
5.4.1 LATS1 and YAP1 protein expression 
Firstly, we checked whether the p.I615V mutation within LATS1 influences the expression 
level of LATS1. Cell lysates of normal human astrocytes (NHA) as a healthy control, 
chromosomally instable U2OS osteosarcoma cell line, NCH149 and NCH82 were prepared 
and the expression level of endogenous LATS1 was analyzed by Western blot. For this, the 
bands corresponding to LATS1 as well as ß-Actin, which served as loading control, were 
quantified (n=3). From these values a ratio was determined for each cell line analyzed. In 
order to normalize the expression levels, the expression level of NHA lysates were set to 1. 
As shown in Figure 5.11A the mutation does not lead to a significant change in LATS1 
expression in NCH149 cells as compared to the other cell lines. The same is true for YAP1 
expression levels (Fig. 5.11B). Hence, the p.I615V mutation does not seem to significantly 
alter the expression level of LATS1 and YAP1 in NCH149 cells compared to wild type 
NCH82 and NHA control. 
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Figure 5.11 LATS1 and YAP1 protein expression levels  
Representative blots of LATS1 (A) and YAP1 (B) are shown. Densitometric quantification of the bands 
normalized to the ß-actin control reveals that the mutation in NCH149 cells has no influence on the 
expression of LATS1 and YAP1 compared to normal NHA control cells. 
 
 
 
5.4.2 LATS1 localization 
Next, cellular localization of LATS1 and YAP1 was investigated using immunofluorescence 
microscopy. Cells were immunostained with a LATS1 antibody that detects both 
phosphorylated and non-phosphorylated LATS1. LATS1 in interphase cells is present in the 
cytoplasm in NCH149, NCH82 and NHA cell lines (Figure 5.12). This indicates that the 
p.I615V muation does not influence the cellular localization of LATS1 in NCH149 cells which 
is comparable to NCH82 and NHA cells wildtype for LATS1. 
 
 
YAP1
Re
l. Y
AP
1 
ex
pr
es
sio
n
0.00
1.00
2.00
NHA U2OS NCH149 NCH82
LATS1
Re
l. L
AT
S1
 
ex
pr
es
sio
n
0.00
1.00
2.00
NHA U2OS NCH149 NCH82
NC
H1
49
NC
H8
2
U2
OS
NH
A
140
43
LATS1
β-Actin
B
NC
H1
49
NC
H8
2
U2
OS
70
NH
A
43
YAP1
β-Actin
A
ns ns
ns nsKDa
KDa
                                                                                                                                        Results 
 58 
 
Figure 5.12 Cellular localization of LATS1  
NCH149 and NCH82 cells were stained with antibodies against LATS1 and γ-tubulin. LATS1 localised 
in the cytoplasm during interphase in all the cell lines. Scale bar, 10 µm.  
 
5.4.3 Density-dependent localization of YAP1 
YAP1 is one of the downstream Hippo pathway targets of LATS1. In proliferating cells YAP1 
translocates to the nucleus and acts as a transcriptional co-activator while in resting cells, 
LATS1 is known to phosphorylate YAP1 causing its cytoplasmic retention and further 
degradation.  
To study the localization of YAP1 in LATS1 mutant NCH149 compared to LATS1 wildtype 
NCH82 cells and NHA cells, non-confluent (low density) and confluent (densely packed) 
cells were fixed and stained with an antibody to YAP1. At low density YAP1 is found 
localised in the nucleus in all three cell types which is normal for proliferating cells (Figure 
5.13 A). Interestingly, at high density, YAP1 localizes to the nucleus in NCH149 cells while in 
NCH82 cells and normal NHA cells the signal is restricted to the cytoplasm (Figure 5.13 B). 
This indicates that although the cells are confluent the negative regulation of YAP1 by 
LATS1 is inactive leading to its uncontrolled translocation to the nucelus.  
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Figure 5.13 Density-dependent intracellular localization of YAP1 
Immunofluoresence microscopy after immunostaining with an antibody against YAP1 (green) and 
DNA stained with Hoechst (blue). (A) Under low density conditions YAP1 localized to the nucleus in all 
three cell lines. (B) At high density normal cytoplasmic localization of YAP1 is observed in normal 
human astrocytes (NHA) and NCH82 cells and abnormal nuclear localization in NCH149 cells. Scale 
bar, 10 µm. 
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5.4.4 YAP1 phosphorylation 
In order to investigate whether a loss of YAP1 phosphorylation by I615V-mutant LATS1 
causes the altered localization of YAP1 in NCH149 cells at high density, the extent of 
LATS1-specific phosphorylation of YAP1 at Ser127 was determined by Western blot 
analysis. The pYAP1 levels in NCH149 and NCH82 cells were compared at low density and 
high density. The phosphorylation of YAP1 at Ser127 was significantly lower in NCH149 
compared to NCH82 cells at both high and low density. Mainly, at high density the levels of 
phosphorylated YAP1 (Ser127) were found to be greatly reduced in NCH149 cells when 
compared to NCH82 cells (P < 0.005) (Figure 5.14). 
 
 
Figure 5.14 pYAP1 (Ser127) Western Blot 
Western blot detection of pYAP1 using a phospho (Ser127) YAP1 specific antibody showed lower 
pYAP1 levels in NCH149 compared to NCH82 at both high and low density (A). Quantification of 
bands normalized to ß-actin confirmed significant decrease in phosphorylation of YAP1 at Ser127 in 
NCH149 compared to NCH82 at both high and low density (B).  
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5.4.5 Interaction of LATS1 and YAP1 
To confirm that the reduced phosphorylation of YAP1 at Ser127 by LATS1 was due to a 
failure of YAP1 binding to LATS1, I performed co-immunoprecipitation experiments. For 
this, I immunoprecipitated YAP1 and analysed for co-immunoprecipitation of LATS1 by 
Western blotting and vice versa. It was observed that in NCH149 cells YAP1 does not co-
immunoprecipitate with LATS1 confirming the lack of interaction between the two proteins 
and hence explaining reduced YAP1 phosphorylation and localization of YAP1 to the 
nucleus. In contrast, the interaction between YAP1 and LATS1 was intact in NCH82 cells, as 
these proteins co-immunoprecipitated in these cells (Figure 5.15). This result confirms that 
the p.I615V mutation impairs the binding of YAP1 to LATS1, hence preventing the 
phosphorylation of YAP1 by LATS1. 
This leads to a conclusion that in NCH149 cells YAP1 binding to LATS1 is impaired due to 
the p.I615V mutation causing reduced phosphorylation of the YAP1. Unphoshorylated YAP1 
then translocates to the nucleus in NCH149 cells. 
 
Figure 5.15 Co-immunoprecipitation of LATS1 and YAP1 
Western blots showing absence of bound fraction of LATS1 and YAP1 in NCH149 cells while LATS1 
and YAP1 were found to co-immunoprecipitate in NCH82 cells. 
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5.5 Chemotherapeutic intervention of Hippo pathway   
Final downstream effectors of Hippo pathway YAP and TAZ are attractive targets for 
chemotherapeutic interventions. Various inhibitors have been identified to target YAP 
directly or indirectly. YAP is dispensable for growth and homeostasis of normal tissues and 
is the final common conduit of upstream signals thus, potentially limiting side effects and 
drug resistance achieved by alternative pathways. Verteporfin is one such small molecule 
that disrupts the YAP-TEAD transcriptional activation complex formation, thereby 
specifically inhibiting YAP1 activity. Since verteporfin has been shown to act in vitro as an 
effective chemotherapeutic agent for cancer cells overexpressing YAP1, this inhibitor was 
chosen for further experiments. 
5.5.1 Dose-dependent toxicity of VP on NCH149 cells 
To analyze the impact of VP on cell viability, the NCH149 and NCH82 cells were treated with 
VP (2 µg/ml and 10 µg/ml) and cell numbers were determined by scoring live cells every day 
for a total of three days (n=3). NCH149 cells which are known to be resistant to most 
chemotheraputic agents as well as radiation, started to die already 24 hours after initiation 
of VP treatment with all NCH149 cells being dead by day 3 (Figure 5.16A). In contrast, 
NCH82 cells, after showing some initial toxicity to VP at day 1, recovered and grew almost 
normally on days 2-3 (Figure 5.16B). 
 
Figure 5.16 Dose-dependent toxicity of verteporfin on NCH149 cells. 
NCH149 and NCH82 cells were incubated with VP for 3 days and cytotoxicity was determined by 
scoring the number of living cells each day. (A) Dose dependent cytotoxicity was induced by VP 
treatment of NCH149 which on day 3 were completely dead. NCH82 cells show initial toxicity on Day 
1 but on day 2 and 3 recover to grow normally.  
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5.5.2 Apoptosis measurement 
In addition, we performed annexin V staining to determine whether the decrease in live 
NCH149 cells is due to apoptosis induced by VP. For this, NCH149 as well as NCH82 cells 
were treated with VP for 1, 2 or 3 days with either 2 or 10 µg/ml. After the respective 
incubation times the cells were stained with FITC-labelled Annexin V and PI. The cells were 
then subjected to flow cytometric analysis and the cells were considered apoptotic when 
they were double positive for Annexin V and PI whereas pre-apoptotic cells were only 
Annexin V-positive (Figure 5.17A). The total sum of apoptotic and pre-apoptotic populations 
was considered for quantification of apoptosis in both the cell lines after VP treatment 
(green boxes in Figure 5.17A). 
In NCH149 cells a dose-dependent increase in the apoptotic cell fraction was observed over 
the period of treatment and almost all the cells were dead by day 3 of VP treatment. In 
contrast, in NCH82 cells an increase of the apoptotic cell fraction related to initial toxicity 
was observed on day 1 but on days 2 and 3 the apoptosis level was comparable to 
untreated controls (Figure 5.17B). Together, this shows that VP specifically kills LATS1-
mutant NCH149 cells but not NCH82 cells which are wildtype for LATS1. 
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Figure 5.17 Measurement of apoptosis after VP treatment 
NCH149 and NCH82 cells were treated with VP and after day 1, 2 and 3 apoptosis induction was 
analysed by staining cells with Annexin V and PI followed by flow cytometric analysis. (A) Examples 
of dot blots at day 3 are shown. Apoptotic (Annexin V / PI double-positive) and pre-apoptotic 
(Annexin V-positive) cells are shown demonstrating the induction of apoptosis by VP in NCH149 
cells. The percentages of apototic and pre-apoptotic cells were calculated together to compare 
apoptosis in NCH149 and NCH82 cells during the 3 day treatment period (B). Dose-dependent 
increase in apoptosis was induced by VP treatment of NCH149 which on day 3 were all dead. NCH82 
cells show initial toxicity on day 1 but on day 2 and 3 recover to grow normally. 
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5.6 Inducible expression of wildtype and mutant LATS1 in the U2OS-tet-on 
system 
With the goal to verify the impact of the LATS1 p.I615V mutation on cell proliferation and 
CIN in an isogenic system, I generated stable U2OS-Tet-on cell lines that inducibly express 
wild type or mutant (p.I615V) LATS1 (Figure 5.18) each fused to a double Flag-tag (2xFlag). I 
performed immunofluorescence at various time points after induction by doxycyclin to study 
the effects of mutant LATS1.  
 
 
Figure 5.18 Sanger sequencing of wildtype and mutant LATS1 plasmids 
Verification of LATS1 mutation by Sanger squencing in pTER2hyg plasmids generated for stable 
transfection of U2OS-tet-on cells, confirms a point mutation A>G at 1843. 
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Firstly, I analyzed the localization of wildtype and mutant LATS1 after overexpression in 
order to demonstrate that overexpressed Flag-tagged LATS1 (either wildtype or mutated) 
behaves like their endogeneous counterparts. For this, U2OS-Tet-on cells with wildtype and 
mutant were grown in medium with (+Dox) or without (-Dox) doxycyclin for 6 days. On day 2 
after induction with doxycyclin the expression levels of wildtype and mutated LATS1 were 
analyzed by Western blotting using an antibody against Flag-tag. Both wild type and mutant 
LATS1 are expressed after induction (Figure 5.19 A). In addition, coverslips were collected 
and fixed every second day after induction and immunofluoresence staining was performed 
with antibody against Flag-tag to detect the presence of induced LATS1. Cellular 
localization of Flag-LATS1 in interphase cells of both wildtype and mutant LATS1 seems to 
be cytoplasmic similar to endogenous LATS1 in interphase cells (Figure 5.19 B). This shows 
that the overexpressed LATS1-versions behave like the endogeneous proteins making the 
cell lines suitable for further experiments. 
 
 
 
 
 
 
 
Figure 5.19 Inducible expression of 2xFlag LATS1 in U2OS-Tet-on cells 
U2OS-Tet-on cells transfected with 2 x Flag wildtype (wt) or mutant (mut) LATS1 were induced by 
doxycyclin. Expression of wildtype or mutant LATS1 was confirmed by Western blotting (A). 
Immunofluorescence shows that overexpressed wildtype and mutant LATS1 localize to the 
cytoplasm during interphase (A). Scale bar, 10 µm. 
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Next, the cells were stained with an antibody against YAP1 to observe whether YAP1 
localizes to the nucleus after overexpression of mutant LATS1. Indeed, already two days 
after induction nuclear localization of YAP1 was observed in confluent LATS1-mutant cells 
but not in non-induced or LATS1-wildtype cells (Figure 5.19). 
 
 
Figure 5.20 YAP1 nuclear localization in mutant-LATS1-expressing cells 
Immunofluorescence staining of induced U2OS-Tet-on cells with an antibody against YAP1 (green) 
and Hoechst shows normal cytoplasmic localization of YAP1 in wild type and un-induced mutant 
cells and nuclear localization in induced mutant LATS1-expressing U2OS cells. Scale bar, 10µm. 
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Finally, I analyzed the impact of overexpression of wildtype and mutant LATS1, respectively, 
on the formation of micronuclei and centriole amplification. For this, cells were fixed 6 days 
after induction of either wildtype or mutant LATS1 (+Dox and –Dox). Preliminary 
experiments upon scoring three times 100 cells show an increase in micronucleus formation 
in induced LATS1-mutant as compared to non-induced LATS1-mutant cells as well as to 
cells expressing wildtype LATS1 (Figure 5.21A). Also, a significant increase in centriole 
amplification in induced LATS1-mutant over both non-induced and wildtype-LATS1 
expressing cells was observed (Figure 5.21B). 
 
Figure 5.21 Micronucleus formation and centriole amplification in mutant-LATS1-
expressing cells 
An increase in the number of cells with micronuclei stained with hoechst (blue) (A) and amplified 
centrioles stained with centrin (green) and CP110 (red) (B) was observed in induced mutant LATS1-
expressing U2OS cells when compared to un-induced mutant and wildtype LATS1 expressing U2OS 
cells (B). Scale bar, 10 µm.  
 
These findings lead to the conclusion that the p.I615V LATS1 mutation impairs binding and 
phosphorylation of YAP1 that results in its nuclear localization. This deregulation of the 
Hippo pathway also seems to contribute to the CIN phenotype by increased micronucleus 
and centriole amplification upon overexpression of mutant LATS1. 
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6 Discussion 
Since Hansemann's work in the late 19th century, abnormal chromosome numbers have 
been recognized as a nearly ubiquitous feature of human cancers (97). Today numerical 
CIN is an established characteristic feature of most human malignancies. For example, a 
current study shows that most late stage cancers contain an average of 60 to 90 
chromosomes (98). Despite its long history and clinical relevance, the study of CIN has yet 
to prove Boveri's postulate that abnormal chromosome numbers are a cause rather than a 
consequence of the cancerous state (99). Although it has been shown that gains and losses 
of whole chromosomes have anti-proliferative effects in untransformed diploid cells, tumors 
exhibiting a large number of gains and losses of chromosomes seem to have a proliferative 
advantage (100; 101).  
Normally, cells that have an abnormal DNA content are prevented from further proliferation 
by a number of cell cycle checkpoints, however, continuous accumulation of chromosome 
changes in a cell population increases the chance of mutations in oncogenes, tumor 
suppressor genes and cell cycle checkpoint genes decreasing the tendency for self-
elimination of aberrant cells (102). Therefore, extreme CIN provides a survival advantage to 
cells by overcoming the protective mechanisms. It is well known that neoplastic 
transformation requires a set of mutations that can be achieved by having abnormally high 
rate of mutations and CIN provides a platform for such a high mutation rate (54). This 
phenomenon is explained by the “mutator hypothesis” that suggests that an initial 
mutation, which creates the "mutator phenotype", allows the accumulation of further 
mutations and the evasion of the normal checks on the cells growth (103; 47). For example, 
in the extreme case of human colorectal cancers that arise from the mismatch repair defect 
were found to have 100,000 genetic mutations and are presumed to have an ability to 
overcome a wide variety of negative controls on proliferation also exhibit significant CIN 
(104). Although, some studies challenge the idea that CIN is important for tumorigenesis 
(105), its prevalence in malignant solid tumors and its contribution to development and 
sustaining ability’s of tumor growth has brought forth the suggestion that CIN plays a 
causal role in tumorigenesis.    
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6.1 Occurance and causes of CIN in Glioblastoma 
Glioblastomas are known to have high levels of CIN making them heterogeneous and 
difficult to treat. Although mechanisms of CIN are comparatively well understood in 
colorectal cancers, there have not been many studies investigating the cause and affect of 
CIN in GBM. In a recent study inactivating mutations in STAG2, a gene coding for subunit 
of cohesin complex that regulates the separation of sister chromatids was shown to cause 
aneuploidy in 5 % of GBM’s (106). In another study oncogenic chromosomal translocation 
event causing fusion of FGFR and centrosomal proteins TACC was shown to induces 
mitotic and chromosomal segregation defects and trigger aneuploidy in 3.1 % of GBM 
tumors (107). The presence of intratumor hererogeneity and chemoresistance and the lack 
of knowledge makes GBM a suitable model to study CIN. 
In the present study, the patient-derived GBM cell line NCH149 was identified in the 
laboratory of Dr. Anne Régnier-Vigouroux that show excessive numerical chromosome 
gains and loses. This cell line was also found to have extreme chemo- and radioresistance. 
Upon further cytogenetic analysis of NCH149 cells and comparing it to another GBM cell 
line NCH82 using M-FISH, it was observed that NCH149 cells exibited extreme aneuploidy 
and cell-to-cell heterogeneity among 24 M-FISH metaphase spreads analysed, while 
NCH82 cells were stably tetraploid (89). It is known that aneuploid cells may or may not be 
chromosomally instable. Numerical CIN is defined by a high rate of continuous gains and 
losses of whole chromosomes therefore; cytogenetic complexity per se cannot be used as 
evidence of CIN. In practice, instability is assessed by following the evolution of cytogenetic 
abnormalities in a tumor cell population over time and by comparing the rate of 
chromosome mutations with that in a normal cell population (108). Alternatively, CIN is 
monitored indirectly by quantifying the incidence of chromosomal losses, gains and 
resulting heterogeneity in a given population of cells. Hence, CIN cells are distinguished 
form merely aneuploid cells by the presence of cell-to-cell heterogeneity. Consequently, in 
this study, interphase FISH experiments were performed for two chromosomes, namely 
chromosomes 2 (large) and 20 (small) of both the cell lines. NCH149 cells were found to 
exibit high clonal heterogeneity confirming the presence of CIN while NCH82 have a major 
tetraploid subclone, this correlates with the M-FISH data. CIN causes a step-wise accumulation 
of cytogenetic changes during tumor growth, which is manifested as clonal heterogeneity 
(45). Heterogeneous tumors are known to generate a larger variety of genetic variants to be 
tested by selection providing a wider adaptive landscape increasing the probability of 
clones reaching fitness for microenvironmental challenges (109). CIN therefore also allows 
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cells to better adapt to changes following exposure to DNA damage encountered during 
radiotherapy protocols, thereby contributing to radioresistant in tumors both before and 
after radiotherapy (110). It has also been previously shown that CIN confers intrinsic 
resistance to chemotherapeutic agents in colorectal cancer cell lines and that presence of 
stable tertraploidy was found incapable of such resistance  (111). This implies that 
karyotypic heterogeneity rather than increased ploidy is responsible for increased treatment 
resistance compared to karyotypically stable cells. Indeed, the high variation of 
chromosome numbers within the population of NCH149 cells strongly indicating the 
presence of CIN could be the cause of resistance to X-ray irradiation and carbon ion 
therapy as observed by Dokic et. al. In contrast, NCH82 cells lower resistant to these 
radiation treatments which can be attributed to the presence of a stable karyotype. Due to 
the observed differences within the population, NCH149 cells are confirmed to be 
chromosomally instable whereas the NCH82 cell line is stably aneuploid (tetraploid). For 
this reason we further examined NCH149 cells in order to determine one of the 
mechanisms leading to CIN in GBM. Chromosomal gains or losses in CIN are known to be 
a result of chromosome missegregation caused by abnormal mitotic spindle assembly, 
impaired microtubule–kinetochore attachment or a weakened spindle assembly checkpoint 
(112). When NCH149 cells were stained with Hoechst, 25% of cells were found to have one 
or more micronuclei per cell. In contrast, in NCH82 cells only about 2% of the cells had 
micronuclei. Micronuclei mainly originate when chromosome fragments or whole 
chromosomes fail to be included in the daughter nuclei after mitosis. These displaced 
chromosomes or chromosome fragments are enclosed by a nuclear membrane and appear 
as micronuclei. Micronuclei are smaller but morphologically similar to the nuclei and can be 
observed by conventional nuclear staining. Presence of micronuclei is an indicator of 
chromosomal missegregation (113). The frequency of micronuclei is used as a biomarker of 
chromosomal damage, genome stability and predicts increased risk of cancer development 
in human populations (114). However, only whole chromosome gains or losses indicate 
numerical CIN hence, we further investigate the presence of whole chromosomes by 
immunofluorescence staining with CREST. In NCH149 cells, 75 % of the micronuclei had 
whole chromosomes with CREST signals meaning that there was high incidence 
chromosomal missegregation. This process of missegregation in NCH149 was clearly 
visualized by staining fixed mitotic cells with CREST, α-tubulin and Hoechst where about 
30% of mitotic NCH149 cells had lagging chromosomes during anaphase and as opposed 
to less than 1 % of anaphases in NCH82 cell line (Figure 5.5).  
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Chromosome missegregation is associated with  supernumerary chromosomes for over 
100 years. Today, it is well known that regulation of centrosome number and function 
underlies bipolar mitotic spindle formation and genetic integrity (115). Here we found that 
NCH149 have higher centriole amplification compared to NCH82 cells. Deregulation of the 
centriole duplication machinery and resulting centriole amplificaton is an obvious source of 
centrosome amplification and aneuploidy in tumors (35). The extent of centrosomal 
aberrations is often correlated with chromosomal instability (CIN) and malignant behavior in 
tumor cell lines, mouse tumor models, and human tumors (116; 117). Hence, the observed 
CIN in NCH149 cells could be a result of supernumerary centrosomes. Centrosome 
amplification, is often associated with multipolar mitosis that lead to aberrant chromosome 
segregation (43; 118). Interestingly, immunofluorescence studies of mitotic cells stained 
with β-actin and γ-tubulin showed that both cell lines NCH149 and NCH82 underwent 
normal bipolar mitosis despite centriole amplification. Comparable to this study the 
frequent occurrence of supernumerary centrosomes in human breast cancer samples was 
associated with surprisingly rare abnormal mitoses (119). Extra centrosomes to bypass the 
SAC by centrosome clustering to undergo bipolar mitosis. However, no signs of 
centrosomal clustering was observed in NCH149 or NCH82 cells. Whether or not 
supernumerary centrosomes undergo clustering to undergo bipolar mitosis is yet to be 
studied in NCH149 cells. Interestingly, by live cell imaging it was observed that NCH149 
cells, on an average took ~30 minutes longer to under go mitosis when compared to 
NCH82 cells (Figure 5.7 B). It is has been recently shown that extra centrosomes or 
chromosomes delay satisfaction of the spindle assembly checkpoint leading to prolonged 
mitosis. Cancer cells having normal number of chromosomes and centrosome can divide in 
less than 20 minutes while doubling the chromosome number adds ~10 minutes while 
doubling the number of centrosomes adds ~30 minutes (120). Therefore, the prolonged 
mitosis duration could be attributed to the higher chromosome number and high centriole 
amplification in NCH149 cells. Prolonged mitosis due to delay in SAC checkpoint has been 
reported to cause missegregation of chromosomes, mitotic slippage causing aneuploidy 
(21). Several other causes of prolonged activation of the mitotic checkpoint in human 
cancer cells have been described such as inactivation of Rb and abnormal MAD2 
expression, abnormal accumulation of cyclinE due to inactivation of the hCDC4 and 
activation of oncogenes such as c-Myc (121). The above phenotypic observations 
demonstrate that NCH149 is chromosomally instable indicated by presence of cell-to-cell 
heterogeneity, chromosomal missegregation and centriole amplification but the causal 
factor for these abnormalities was unknown. NCH149 cells therefore provide a suitable 
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system to investigate connection between CIN and genetic mutations and hence whole 
exome sequencing of NCH149 cells was performed to identify mutations that might cause 
CIN. Analysis of the whole exome sequencing data identified mutations in 24 different 
genes found in the tumor and in the cell line but absent in healthy tissue (Table 5.1). Of 
these LATS1 p.I615V mutation was most interesting with regard to tumorigenesis and CIN. 
Mutation induced defects in mitotic spindle assembly, mitotic check point, sister chromatid 
cohesion and centrosome amplification have been shown to cause chromosomal 
missegregation leading to CIN (29). So far, mutations in genes regulating these processes 
such as STAG2 and MAD2 have been identified to be possible causes of CIN. Other genes 
such as BRCA1, BLM and ATM that are known keep genetic alterations to a minimum, and 
thus when they are inactivated, mutations in other genes occur at a higher rate (122). 
However, LATS1 mutations are rare in cancer tissues in general and especially in GBM. 
Interestingly, a recent study has uncovered LATS1 p.I615T mutation by silico analysis 
provides evidence that LATS1 mutations in this region may play a role in CIN and drive 
human tumor development (123). 
6.2 LATS1 mutation mediated deregulation of Hippo pathway and its role in 
CIN 
In the present work I have attempted to deliniate the effect of the identified LATS1 p.I615V 
mutation on Hippo pathway function in NCH149 GBM cells. Classically identified within the 
Hippo signaling pathway, LATS1 also acts independently of this pathway, possessing 
multiple functions including regulation of cell proliferation, cell death and cell migration, and 
plays a governing role in mitosis and maintenance of genetic stability. LATS1 is a tumor 
suppressor gene. This was initially recognized by genetic studies in Drosophila 
demonstrating that heterozygous loss of LATS1 produced a wart-like phenotype 
characterized by excessive overproliferation of imaginal disc epithelial cells of Drosophila 
(124). Complete loss of LATS1 causes embryonic lethality in flies, which highlights the 
importance of LATS1 function (125). Downregulated LATS1 gene expression was found in a 
variety of tumor types including soft tissue sarcomas, breast, myxoid liposarcoma, 
leiomyosarcomas and malignant fibrous histiocytoma (126). In one study, LATS1 
downregulation was correlated with poor prognosis in glioma patients (78). In contrast there 
was no significant difference in the protein expression levels of LATS1 or YAP1 in LATS1-
mutant NCH149 cells when compared to LATS1 wild type NCH82 cells and  normal human 
astrocytes.  
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YAP1 overexpression was observed in many cancers such as mesotheliomas, non-small-
cell lung carcinoma and brain tumors like GBM (127; 128). In spite of the high frequency of 
YAP1 overexpression, a relatively low incidence (5 –15 %) of amplification of the human 
chromosome 11q22 amplicon containing YAP1 gene has been reported in human tumors 
(129). This led to the speculation that elevation of YAP1 protein levels in cancer may not 
only due to gene amplification, but a result of deregulation of the Hippo pathway. The direct 
upstream controller of YAP1 activity is LATS1 and mutations in LATS1 could affect YAP1 
negative regulation. Therefore, immunfluoresence staining of NCH149, NCH82 and NHA 
cells was performed which shows normal nuclear localization of YAP1 in all cell types at low 
density. Interestingly, YAP1 immunofluoresence staining of NCH149 cells at high density 
showed nuclear localization while in NHA and NCH82 cells YAP1 was found localized in the 
cytoplasm. It is known that in response to cell contact inhibition the Hippo pathway is 
activated leading to LATS1-mediated YAP1 phosphorylation with subsequent cytoplasmic 
retention and degradation of YAP1 (71).  When cells proliferate at low density the Hippo 
pathway is inactive thereby facilitating the translocation of YAP1 into the nucleus to initiate 
trasciption of various growth promoting genes. Nuclear localization of YAP1 has been 
identified before during immunohistochemical survey of YAP1 expression in meningioma 
tumors (130). This suggests that the negative regulation of YAP1 by the Hippo pathway is 
not functional in p.I615V LATS1-mutant NCH149 cells. To further investigate the extent of 
YAP1 phosphorylation at Ser127 by LATS1, Western blot analysis was performed and 
compared in high and low density cells. Accordingly, pSer127-YAP1 levels were 
significantly lower in NCH149 cells with mutant LATS1 compared to NCH82 cells which are 
wildtype for LATS1. These results strongly argue that the phoshoprylation of YAP1 by 
LATS1 is impaired in NCH149 cells due to the presence of a mutation in the YAP1-binding 
domain of LATS1. This finding is supported by co-immunoprecipitation experiments, which 
showed that LATS1 and YAP1 did not co-immunoprecipitate in LATS1-mutant NCH149 
cells. Mutations in YAP1 that lead to decreased phosphorylation by LATS1 or decreased 
14–3–3 binding have been reported earlier (131; 132). In YAP1 S381 mutant cells YAP1 
overexpression and nuclear localization was observed due to loss of S318 phosphorylation 
and subsequent degradation (133). The correlation between LATS1 dysfunction due to 
downregulation or mutations and its  involvement in cancer development has been widely 
discussed. However, LATS1 mutations preventing binding and phosphorylation of YAP1 
have not been identified up to now in human cells.  
There have been some studies that describe the involvement of the Hippo pathway in 
maintenance of genetic integrity. LATS1 dynamically localizes to centrosomes and the 
mitotic spindle apparatus, including the central spindle, and contributes to the regulation of 
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proper chromosome segregation during mitotic progression and cytokinesis (74; 134). Cells 
expressing N-terminally truncated LATS1 show supernumerary centrosomes as well mitotic 
defects including chromosomal missegregation and cytokinesis failure. Also, overexpression 
of YAP1 has been shown to cause genomic instability in medulloblastoma (68). To 
determine if Hippo pathway deregulation by p.I615V-mutant LATS1 plays a role in CIN 
development, we established U2OS cell lines inducibly expressing wildtype and p.I615V-
mutant LATS1. Upon induction of mutant LATS1, YAP1 was found localized in the nucleus 
even at high density while YAP1 was cytoplasmic in induced wildtype and non-induced 
cells. Preliminary experiments also indicated an increase in micronucleus formation and 
centriole amplification when compared to the induced wildtype and non-induced cells. 
There are various theories on how CIN could develop as a result of LATS1 mutation and 
resulting Hippo pathway deregulation. First, enforced expression of NDR1, a LATS1-related 
kinase, is known to enhances centrosomal overduplication in a kinase activity-dependent 
manner (135). The p.I615V mutation lies within the protein binding domain (PBD; aa.656–
758)  with is known to be important form MOB1 binding. Therfore mutation mediated loss of 
LATS1-MOB1 could in theory increase MOB1-NDR1 complex leading to centrosomal 
overduplication. Second, YAP1 overactivation due to LATS1 mutation may cause Akt 
phoshorylation and activation through IGF2 causing downregulation of ATM-Chk2-p53 
pathway leading to radioresistance and genomic instability (68). During mitosis CDC2 is 
known to form a complex with LATS1 at the centrosome and phosphorylation of Ser613 
occurs. The LATS1 p.I615V may interfere with phosphorylation at this site leading to CIN 
(136). These effects of LATS1 mutation on the above pathways leading to CIN development 
remain to be explored in NCH149 cells.  
6.3 VP a specific cytotoxic agent for LATS1 mutant YAP1 hyperactive cells 
An intriguing aspect of the Hippo pathway is that its components interact through well 
characterized structures such as WW-domain and PPxY motifs. These properties of the 
Hippo pathway impart significant potential and advantages to be an attractive target for 
drug development (137). However, to date, few small-molecule inhibitors have been 
discovered that target the Hippo pathway.  
Recent progress in the search for small-molecule Hippo pathway modulators has identified 
Verteporfin (VP) to be a specific inhibitor of YAP1 (81). VP has been shown to act as an 
effective chemotherapeutic agent in vitro for mainly those cells overexpressing YAP1. Since 
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in this study NCH149 was shown to have YAP1 hyperactivity VP was chosen for targeting 
YAP1-TEAD in NCH149 cells. As mentioned before NCH149 cells are highly resistant to 
standard chemotherapeutic drugs and radiation. Nevertheless VP did induce dose-
dependent toxicity in NCH149 but not in NCH82 cells. This toxicity observed is attributed to 
apoptosis induced by VP specifically in NCH149 and not in NCH82 cells. This appears to be 
due to a dependency of NCH149 cells on YAP1 activity for growth and proliferation. The 
recent discovery of G-protein coupled receptors (GPCRs) as regulators of the Hippo-
YAP/TAZ pathway has broadened the scope of upstream drug targets including a wide 
variety of extracellular ligands and receptors. Dobutamine (a GPCR β-adrenergic receptor 
antagonist) was recently recognized as an inhibitor of the Hippo pathway (79). However, 
targeting the downstream YAP1-TEAD interaction directly has proven to be more 
successful. YAP and TAZ are transcriptional co-activators with no known catalytic activity. 
Thus, inhibiting the function of YAP1 and TAZ require targeting protein-protein interactions 
(138). VP was found to be effective in inhibition of growth and proliferation of retinoblastoma 
cells in vitro (80). In vivo experiments in inducible YAP1 transgenic mouse model showed 
that VP treatment suppressed YAP1-induced hepatomegaly and more importantly showed 
no effect on wild-type non-transgenic controls (81). As YAP1 is the final effectors of the 
Hippo pathway, direct inhibition of YAP1–TEAD may reduce possible side effects that might 
be caused by targeting upstream components that probably affect multiple intracellular 
signalling pathways. Also, YAP1-TEAD pathway is not active in normal tissues, drugs 
disrupting this interaction have the potential for increased cancer specificity and minimal 
healthy tissue toxicity making it a suitable drug target. Therefore, this study provides 
additional proof that VP could be an effective targeted therapy against LATS1-mutant or 
YAP1-hyperactive tumors. 
In summary, the findings presented here establish for the first time a model wherein a 
LATS1 mutation (p.I615V) in the YAP1 binding domain hinders the interaction of the two 
proteins resulting in significantly decreased YAP1-Ser127 phosphorylation. YAP1, an 
oncogene, as a result localizes to the nucleus and binds to TEAD to activate transcription of 
tumor promoting genes (Figure 6.1). This deregulation of the Hippo pathway as a result of a 
LATS1 mutation also seems to increase chromosomal instability in cells expressing mutant 
LATS1. 
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Figure 6.1: Deregulation of the Hippo pathway due to LATS1 mutation 
Schematic illustration of the proposed model wherein the LATS1 p.I615V mutation leads to 
cancelling of YAP1 phosphorylation causing its nuclear translocation. This leads to YAP1-TEAD 
binding and transcriptional activation of tumor promoting genes and chromosomal instability. VP, 
known to disrupt the YAP1-TEAD interaction, selectively kills cells with such YAP1 hyperactivity. 
6.4 Outlook 
In the present work first evidence could be found that muations in the YAP1-binding domain 
of LATS1 deregulate the Hippo pathway by preventing negative regulation of YAP1. 
However, the clinical significance of this finding must be estimated possibly by 
immunohistochemical staining of GBM tumor sections to look for YAP1 nuclear localization 
along with screen to identify single nucleotide changes using derived cleaved amplified 
polymeric sequence (dCAPS) method (139).  
To analyze whether the CIN phenotype can be reset, "rescue" experiments are necessary 
by siRNA-mediated "knock down" of mutant LATS specifically and the overexpression of 
wild type LATS. Moreover, to verify the effect of an amino acid substitution in LATS1 on the 
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protein itself, in silico studies could be performed to observe why the mutation affects YAP1 
binding. Furthermore, it may be analyzed whether this mutation affects interactions of 
LATS1 with other proteins including MOB1, NDR kinase, TAZ and CDK1 which may have an 
impact on mitotic processes as well. Furthermore, experiments should be carried out to 
delineate mechanistically how mutant LATS1 leads to the development of CIN. One 
possibilty is overactivation of the NDR1 kinase that is known to cause CIN mediated by 
MOB1. Another is YAP1-mediated Akt activation and cell cycle checkpoint suppression or 
IGF2 activation to inhibit the DNA repair machinery (68).  
Preliminary experiments in U2OS cells expressing wildtype and mutant LATS1 suggested 
that the identified mutation caused an increase in micronucleus formation and centriole 
amplification. To determine whether this leads to CIN in these cell lines, M-FISH analysis or 
interphase FISH could be performed to analyze for increased rates of chromosomal gains or 
losses. Furthermore, U2OS cells are known to be chromosomally aberrant from the 
beginning (140). Therefore, inducible diploid, chromosomally stable cells expressing 
wildtype and mutant LATS1 should be generated using for example the HCT116 colon 
cancer cell line, so that the development of CIN can be clearly monitored. In addition 
microarray analysis of RNA isolated from wildtype and mutant LATS1 expressing cells could 
be performed to identify changes in transcription of genes involved in tumor progression 
and CIN. 
Verteporfin treatment showed that the cytotoxicity was specific to LATS1-mutant cells with 
YAP1 hyperactivity as in NCH149 cells. VP toxicity experiments must be performed in cell 
lines inducibly expressing mutant LATS1 along with healthy controls to specifically allocate 
this effect to the I615V-LATS1 mutation. 
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